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Abstract: Visual disorders are a massive economic and personal burden. Two leading causes of blindness 
in the United States, Glaucoma and Age-Related Macular Degeneration (AMD), currently have no cure [1, 
2]. A major secondary issue in these diseases, often untreated, is the development and ongoing presence of 
scars in the eye [2, 3, 4]. While scarring is a byproduct of the wound healing process [5], this scarring in 
the eye can lead to blindness [6, 7]. In the retina the scarring process is a result of ongoing retinal gliosis, 
mediated by the structural Müller glial cells [8, 9, 10]. Two well-characterized markers of this process are 
the cytoskeletal Intermediate Filament (IF) proteins vimentin and the glial fibrillary acidic protein (GFAP), 
which become overexpressed as a stress response [11, 12]. Importantly, interfering with the soluble, non-
cytoskeletal forms of these two proteins with the small molecule withaferin A (WFA)  has anti-proliferative 
[13] and anti-migratory effects [14, 15], two cellular processes integral to scarring [16, 17, 18]. As with 
many other proteins, GFAP and vimentin can be regulated by a number of different post-translational 
modifications (PTM). One PTM which the IF proteins are subjected to is citrullination [19].  
Here, I have identified citrullination as an injury-induced response in the retina. Increases in 
citrullination are seen as early as 1 day after injury. This citrullination occurs along GFAP and vimentin 
filaments. I have identified two sites on GFAP that are citrullinated after retinal injury. The enzyme 
responsible for this injury-induced citrullination in the retina was PAD4. The citrullinated form of GFAP 
was targeted initially in a retinal explant system by the pan-PAD inhibitor Cl-amidine using an  intravitreal 
injection model. The treatment decreased the levels of GFAP protein indicating a reduction of the gliotic 
phenotype. These findings mimicked what was seen in a mouse model of glaucoma, the DBA/2J mouse 
line. In this system, changes in citrullination within the glaucomatous eyes preceded changes  in GFAP 
protein levels. These findings identify citrullination of GFAP as a major response to 
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injury in the retina, mimicking the disease pathology of glaucoma. The ability to target these proteins  
within the retina, initially, and in the whole eye with an intravitreal injection to reduce a major gliotic 
marker has implications for the future development of therapeutics for treating the often undiagnosed 
gliosis associated with retinal disorders. 
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Chapter 1 
 
 
 
1.1 Overview 
Introduction 
 
Visual disorders are a massive economic and personal burden. Two of the leading causes of 
blindness in the United States, Glaucoma and Age-Related Macular Degeneration (AMD), currently have 
no cure [1, 2]. A major secondary issue in these diseases, often untreated, is the development and ongoing 
presence of scars in the eye [2, 3, 4]. While scarring is a byproduct of the wound healing process [5], this 
scarring in the eye can lead to blindness [6, 7]. It can occur in the cornea and the retina, and closely 
resembles the scarring seen after injury to these tissues [20]. In the retina the scarring process is a result of 
ongoing retinal gliosis, mediated by the structural Müller glial cells [8, 9, 10]. 
Müller cells are the major glial cells in the retina [8, 21]. Müller cells stretch the entire width of the 
retina, come into contact with all neuronal subtypes [22], and are the reactive cells in retinal gliosis [8]. 
Two well-characterized markers of this process are the cytoskeletal Intermediate Filament (IF) proteins 
vimentin and the glial fibrillary acidic protein (GFAP), which become overexpressed as a stress response 
[11, 12]. The absence [23, 24, 25, 26, 27] or overabundance [28] of these two proteins in glial cells alters 
overall tissue health in response to injury the CNS. Importantly, interfering with the soluble, non-
cytoskeletal forms of these two proteins with the small molecule withaferin A (WFA) has anti- proliferative 
[13] and anti-migratory effects [14, 15], two cellular processes integral to scarring [16, 17, 
18]. 
 
The function of the soluble forms of these IF proteins and what roles they have in scarring highlight 
the importance of understanding the multiple ways this pool of IF proteins is regulated. As with many other 
proteins, GFAP and vimentin can be regulated by a number of different post-translational modifications 
(PTM). While phosphorylation of the IF proteins has been studied extensively [29, 30, 31] and is known to 
be important in controlling the levels of soluble and cytoskeletal IF protein [32], it is only one of several 
PTMs that can alter this balance [31]. Another PTM which the IF proteins are subjected  to 
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is citrullination [19]. Citrullination is a relatively understudied PTM that functionally removes a positive 
charge and disrupts the polymerization of GFAP and vimentin [33]. 
Citrullination is becoming known as a disease related process [34]. Increased levels of citrullinated 
GFAP are present in brains of Multiple Sclerosis (MS) [35, 36] and Alzheimer’s Disease  (AD) patients 
[19], and citrullinated vimentin is a major biomarker of rheumatoid arthritis severity [37]. Interestingly, 
total levels of citrullinated proteins are increased in both AMD [38] and glaucomatous eyes [39]. This 
increase of disease related citrullination in ocular disorders which can include a scarring pathology [4, 40] 
and the effect that citrullination has on the solubility of the IF proteins [33] is not known. In my thesis, I 
will demonstrate that citrullination occurs on the intermediate filaments in the retina during retinal gliosis, 
and identify the specific enzyme(s) responsible for citrullination of GFAP. Finally, using small molecule 
inhibitors, I will demonstrate that citrullination can be reduced in an injury model. 
 
 
1.2 Visual Disorders and Scarring 
 
Visual disorders encompass a broad range of conditions that interfere with the ability of the eye to 
sense light and transmit signals to the brain (Fig. 1-1). They also represent a large economic burden, and 
dramatically diminish the quality of life in the people they affect, often irreversibly [41, 42]. These 
disorders can affect numerous different parts of the eye. For instance, Age-Related Macular Degeneration 
(AMD) is a deterioration of the macula, the major light-sensing region of the retina [43], while glaucoma 
is a condition damaging the optic nerve that is often due to disruptions in the normal maintenance of 
pressure in the eye [44]. The cornea, at the anterior aspect of the eye, is also subject to a number of different 
types of injuries. These injuries, such as chemical injuries [45] can penetrate different tissues and, by 
causing the cornea to lose its transparency, prevent light from reaching the retina. The retina is also subject 
to injuries, whether secondary to corneal injury [45, 46] or directly to the retina as in blast injury  [20, 47]. 
Unfortunately, each of these injuries can lead to an irreversible blindness. 
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Figure 1-1. The Path of Light through the Eye 
 
Light travels through the cornea and ultimately becomes focused onto the macula, within the retina. Light 
is converted to an electrical signal and transmitted to the brain through the optic nerve. Injury at the cornea 
obstructs the path of light to the retina. Injury to the retina or optic nerve can either obstruct light reception 
in the retina or prevents transmission of electrical signals to the brain. Modified from [48].  
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In these ocular conditions, a major secondary factor is the development of a chronic debilitating 
scar [4, 40]. This scarring is a progressive pathological consequence of cells attempting to heal the injury 
site to provide support to surviving cells and prevent the spread of damage [49]. In the cornea and retina 
this scarring can lead to the prevention of normal ocular function [6, 7]. In the cornea, this scarring is a 
result of fibrotic processes that leaves the cornea opaque and incapable of properly transmitting  light. In 
this process, corneal keratocytes develop into fibroblasts to be able to fill the wound left from injury, and 
eventually differentiate into myofibroblasts, which cause the opacity that can lead to blindness [50].  
In the retina, scarring can occur in several different locations depending on the pathological trigger. 
Scars can be caused by proliferation of Müller cells into the subretinal space, leading to a  subretinal scar 
(Fig. 1-2). These subretinal scars occur between the neural retina and the retinal pigment epithelium (RPE), 
which in turn can lead to retinal detachments similar to those seen in proliferative vitreoretinopathy (PVR) 
[51]. These detachments can be treated surgically, but have a high rate of recurrence [51]. At the site of 
interaction between the vitreous and the retina, the vitreoretinal surface, scars are often formed by process 
extension along the retinal surface and into the vitreal space [40, 52] (Fig.1-2). These cell processes are 
extensions of Müller glial endfeet, normally a part of the inner limiting membrane of the retina in the layer 
of axons that connect the retina to the brain. The process extension is driven by increases in GFAP and 
vimentin expression within the cell. These vitreal scars, called epiretinal membranes,  are also found in the 
aging eye, with their presence more frequent and their size increased in patients with AMD. As new data 
suggest that Müller glia may also work as a kind of “optical fiber” to deliver light correctly to the 
photoreceptors [53], such scars on the vitreal surface not only disrupt the normal architecture of the retina 
but can also alter the path light takes through to the photoreceptors. 
Both subretinal and epiretinal scars are generated through Müller glial reactivity [17, 40]. While 
the Müller glia are responsible for maintaining normal retinal homeostasis, their reactive nature in injury 
and disease creates problems leading to blindness. This reactivity, called retinal gliosis, is an attempt to 
stabilize the retina after injury, but frequently leads to disruptions of normal retinal function when gliosis 
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Fig. 1-2. Anatomy of Retina and Location of Scars. 
 
(A) Muller glial cells (yellow) come into contact with all neuronal subtypes (red) and photoreceptors (blue) 
to provide support. (B) In injury or during disease, the cornea and the retina react and can form scars. 
Muller glial cells can proliferate to form subretinal scars or extend processes to form epiretinal membranes, 
impeding the transmission of light to the photoreceptors. Modified from [54]. 
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becomes chronic. Controlling the negative aspects of chronic gliosis could lead to therapeutic 
improvements [13]. 
 
 
1.3 Retinal Gliosis and IF Proteins in Müller Glial Cells 
 
The majority of visual disorders affecting the retina have an underlying gliosis [22]. This process 
is very similar to the gliosis seen in the rest of the central nervous system. While reactive astrocytes are 
responsible for gliosis in the brain [55], in the retina the majority of the reactivity is due to the Müller glial 
cell. Müller glia are the structural cells of the retina, spanning the entire width of the retina and coming into 
contact with every neuronal cell type. In an uninjured state, the Müller glia provide homeostatic support to 
all the neuronal subtypes [22]. They contribute to the maintenance of the blood- retinal barrier, control 
retinal pH, and are thought to be involved in the cone visual cycle [22, 56]. In response to pathological 
changes in the retina, the Müller glia become reactive. This reactivity involves both general and specific 
changes. The general changes are present regardless of the type of pathology, and include the upregulation 
of vimentin and GFAP in Müller cells. The specific changes depend on the type of insult to the retina, but 
also result in alterations to normal Müller cell function. 
Experimental models to study Müller cell reactivity include chemical injuries, mechanical 
manipulations, laser and light injuries, and genetic models [17, 57, 58, 59, 60]. In experimental retinal  
detachments, retinas injected with an experimental marker for Müller cell nuclei were proliferative, with 
nuclei migrating along vimentin filaments towards the photoreceptors, where they presumably go on to 
form glial scars [17]. In a genetic mouse model in which Müller glial cells overexpress human Bcl2 [57], 
Müller cells undergo increased and early apoptosis. In this apoptotic retina, photoreceptors become 
detached from the RPE. Subsequently, the photoreceptors begin to die after Müller glial cells die,  
highlighting the importance of the Müller glia for the maintenance and health of photoreceptors. In a genetic 
mouse model of glaucoma (DBA/2J mice), several iris proteins are mutated, resulting in increased 
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intraocular pressure and damage to the optic nerve [58, 59]. This model system shows Müller reactivity, 
indicated by increased GFAP expression early in pathology [60] 
Retinal gliosis has recently been identified an associated process in chemical injuries, such as 
experimental corneal alkali injury [13]. This mimics the clinical condition [45], which is also accompanied 
by increases in intraocular pressure (IOP) [61]. In this system, regulators of Müller glial cell cycle are 
altered to allow for proliferation. Cyclin D3 and PCNA are increased, while p27kip1  is decreased following 
injury [62, 13]. The use of withaferin A (WFA) in the alkali injury model, a small molecule known to bind 
soluble forms of the IF proteins, returned the expression of these markers to patterns seen in the uninjured 
eye as visualized by immunohistochemistry, in a vimentin-dependent manner. Importantly in this model 
both the cornea and the retina undergo scarring, and the use of WFA is able to show clinically relevant 
improvements to both tissues, emphasizing the importance of the intermediate filament proteins [13, 15] 
 
 
1.4 IF Proteins in Scarring and Fibrosis 
 
The intermediate filaments are a large class of proteins that are categorized by their sequence 
similarity [63, 29]. They are the type I and type II keratins, the type III IFs including GFAP, vimentin, 
desmin, syncoilin and peripherin, the type IV lamins, the type V neurofilaments and the type VI proteins, 
restricted to the lens [for review 63, 64]. GFAP and vimentin are the main IF and cytoskeletal proteins in 
glial cells of the central nervous system. Both proteins are present in reactive Müller glia. 
GFAP and vimentin are known to play major roles in the normal scarring. The role of the IF 
proteins in scarring is becoming increasingly important in retinal health, and insights into these roles 
frequently come from knockout mice. Vimentin and GFAP knockout mice show no apparent phenotype  in 
an uninjured state and develop normally [25]. However, these mice show changes in injury response. 
Fibroblasts from vimentin knockout (vim-KO) mice [65] are impaired in their ability to fill in a scratch 
wound in culture, and contract collagen more slowly, in part due to a disrupted actin cytoskeleton. In   the 
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adult vim-KO mice subject to full-thickness dermal injury, fibroblasts exhibit a delayed differentiation into 
myofibroblasts, again showing a disruption in the actin cytoskeleton compared to similarly injured wild-
type mice [66]. In GFAP and vimentin double knockout mice subjected to stab wound in the brain, glial 
scars were significantly less dense and bled more frequently than seen in wild type mice. In lesioned 
hippocampal sections, IF protein double knockout mice also displayed significantly shorter process 
extension compared to wild type controls, and this absence of intermediate filaments  in  astrocytes resulted 
in the greater loss of synapses after lesion [27]. 
In the retina, the absence of GFAP and vimentin in experimentally detached retinas frequently led 
to tearing near the vitreoretinal surface, and these retinas were subject to more tearing during normal 
handling [23, 24]. Retinas deficient in GFAP and vimentin are also more accepting of transplanted retinal 
cells. When retinal cells from P0 mice were injected into wild type adult mice, the cells did not migrate 
away from the injection site and showed limited neurite growth, while reactive gliosis was observed within 
the weeks following transplantation. In the IF protein double knockout mice, however, retinal cell 
precursors migrated and were able to extend neurites, occasionally as far as the optic nerve [26]. The 
integration and extension of neurites in this knockout system places an emphasis not only on experimental 
methods that could be employed to control IF proteins, but identifies the regulation of these proteins as 
integral injury response to any clinical attempt to regenerate retinas with vision loss. 
While the formation of glial scars and the integration of neuronal precursors seems to be 
dependent on the cytoskeletal form of the IF proteins in these systems, recent work has identified the 
soluble, non-cytoskeletal form of these proteins as an integral target for clinically relevant improvements. 
Previous findings discovered that targeting soluble vimentin with WFA improves outcomes in several  
clinically relevant model systems representing injury to the eye. In addition to the improvement in retinal 
gliosis observed by WFA binding in the alkali injury model mentioned above [13], WFA was able to 
target vimentin in both a corneal fibrosis model and a glaucoma model of fibrosis [67]. In the corneal 
fibrosis model, treatment with WFA decreased levels of smooth muscle actin, as a marker of 
myofibroblast  differentiation  and  conversion  to  a  fibrotic  phenotype.  It  also  improved  corneal  
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transparency, a key feature of overall corneal health [15]. In a rabbit glaucoma model, treatment with WFA 
led to a decrease in cell proliferation, and altered the survival of aqueous filtration blebs, displaying 
improved drainage of fluid in the eye in glaucoma [67]. The discovery that soluble forms of the IF proteins 
are targets for clinically relevant improvements in these systems, and that WFA can bind these soluble 
forms, highlights the importance of understanding the soluble IF proteins. Recent research has identified 
novel roles for these soluble IF proteins, which is discussed below. 
 
 
1.5 Roles of Soluble IF Proteins 
 
Biochemical examination of GFAP and vimentin was initially difficult, as they are often considered 
insoluble under normal physiological conditions. Many of their physical properties can be altered by 
different conditions, such as salt concentration or pH. High salt concentrations and high pH (>8.4) drives 
polymerization [68] of the IF proteins. For this reason, the insoluble, long filaments were  the best studied 
for a long time. The traditional solubilization of the intermediate filaments requires the use of 8M urea, 
with lower concentrations leading to dimerization and tetramerization and the inability to isolate 
filamentous forms [69, 70, 71]. 
The ability to extract soluble IFs using a low salt buffer [72] led to the identification of tetrameric 
vimentin as a basic vimentin subunit in normal cells. It also allowed for the approximation of the ratio of 
soluble to insoluble in a non-pathological state. Approximately 90-95% of the pool of these proteins falls 
into the insoluble fraction in a physiological state [72], while 5-10% is soluble. Importantly,  the extraction 
of soluble forms of vimentin has led to important discoveries about how the soluble pool is regulated 
differently from the insoluble fraction. The difficulty of investigating the soluble form of IF proteins in 
isolation from the cytoskeletal forms has only recently been overcome through the use of molecular biology 
tools [73, 74] 
Soluble vimentin has several important functions that are non-cytoskeletal. Closely related function  
to  its  role  in  the  cytoskeleton,  soluble  vimentin  is  extremely  important  for lammellipodia 
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formation [73] by forming the leading edge of processes in fibroblasts. In lamellipodia of fibroblasts there 
is a distinct lack of filamentous vimentin, while small vimentin particles can be clearly seen. Additionally, 
when vimentin filaments were forcibly broken down after the addition of a mimetic peptide, which inhibits 
vimentin filament assembly [73, 75], lamellipodia like structures were increased. Soluble vimentin also 
plays a very important role as a chaperone for the transport of kinases to the nucleus. Soluble vimentin in 
injured neurons was shown to transport the activated form of extracellular signal- regulated kinase (ERK) 
to the nucleus 76] through direct binding to importin-β and transport toward the nucleus through interaction 
with dynein. Recent work has also shown that in vimentin knockout mice, translocation of pERK to the 
nucleus was impaired [77]. Additionally, vimentin is differentially phosphorylated in corneal 
myofibroblasts, and they maintain higher levels of vimentin in the soluble pool compared to fibroblasts 
[77]. This phosphorylation makes vimentin more sensitive to WFA treatment than the unphosphorylated 
form. This interplay also affects the interaction of vimentin with ERK, and as  a result, WFA also blocks 
ERK nuclear translocation. Ultimately, these changes in phosphorylation of vimentin impaired cell 
spreading in these cells as a result of the disrupted interaction between soluble vimentin and the focal 
adhesions necessary for rearrangement during the spreading process, an important finding with regards to 
cell migration. Vimentin may also serve as a scaffold for other signaling transduction molecules, as β-3-
adrenergic receptor signaling was significantly reduced following breakdown of vimentin filaments [78]. 
Mutated soluble GFAP binds portions of the proteasome to disrupt normal proteolytic function [79], often 
leading to GFAP containing aggregates. As discussed above, the use of WFA to bind soluble GFAP in 
retinal gliosis led to improvements in tissue health at 7 days [13]. 
The functions of soluble IF proteins are often overlooked in favor of the cytoskeletal functions 
when examining reactive conditions such as gliosis. With increasing knowledge about the roles of the  
soluble IF proteins and the impact they have on tissue health, however, the production, maintenance, and 
regulation of this soluble pool become important avenues of research for therapeutic developments, 
specifically in ocular health. 
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1.6 IF Protein Regulation 
 
Filaments are highly conserved in structure, with all IFs containing an N-terminal head domain, a 
C-terminal tail, and an alpha-helical rod domain. While the head and tail domains can differ greatly, the 
rod domain is very highly conserved [80].  This rod domain is further structured into coiled-coil and linker 
domains [81]. The rod domain is critical to the filamentous structure of the protein, as the rod domains 
interact to hold together polymers of intermediate filaments [82]. All type III IFs have a conserved cysteine 
[13], which is believed to be important as a sensor of the cellular environment. When vimentin was 
incubated with zinc, polymeric structures were able to form, while blocking this cysteine resulted in an 
increase in soluble vimentin [83]. Additionally, when vimentin deficient cells were transfected with a 
construct modifying cysteine to serine, filamentous networks were incapable of forming. Corroborating 
evidence from experiments with WFA, disruption of this cysteine decreased cell spreading, as measured 
by cytoplasmic area. Interestingly, magnesium was seen to compete with zinc in vimentin binding, with 
zinc being preferentially bound, even at levels too low to induce polymerization. This implies a role of this 
cysteine, and its control by zinc, in the maintenance of homeostatic levels of soluble vimentin as well as in 
the polymerization into filaments. 
The head and tail domains of vimentin are known to modulate other interactions, including the 
diameter of the filament and its formation beyond dimers and tetramers, as seen by electron microscopy 
[69]. When the head domain was deleted, only aggregates of dimers and tetramers were found, despite the 
use of polymerizing conditions. Deletion of the tail domain displayed IFs of mixed diameter, mostly larger 
than normal. This interaction of the tail likely helps to compact the filaments to 10 nm through interactions 
with the rod domains between antiparallel dimers [84]. The head and tail domains are also responsible for 
interactions with other proteins [85]. 
The highly conserved nature of the IF structure is important for the interactions which regulate the 
formation of the filamentous forms of the IF proteins. As outlined in figure 3, the IFs GFAP and vimentin 
are translated as monomers (1-3A) and quickly form parallel dimers (1-3B), directly interacting 
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Figure 1-3. Formation and Assembly of Intermediate Filament Polymers 
 
The assembly of intermediate filaments takes place in a stepwise fashion. Initially polarized monomers are 
translated (A), and quickly form parallel dimers (B). Two dimers then interact in an anti-parallel fashion to 
form a tetramer, the basic soluble subunit under physiological conditions (C, E). 8 dimers interact to form 
a unit length filament (D, F). These unit length filaments go on to form short filaments, or “squiggles”  (G) 
and long polymers to form the cytoskeleton (H). Modified from [31]. 
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through their rod domains. This dimer then interacts in an anti-parallel fashion with another dimer to form 
a tetramer (1-3C, E). This tetramer is considered a soluble unit, as it is the most basic unit that exists in the 
physiological state. Eight tetramers form a unit length filament (1-3D,F) [31], which can interact with other 
unit length filaments to form short filaments which appear as "squiggles" (1-3G) [86] or the long, 10nm 
thick filaments that have been described in most studies (1-3H). Unlike the polar addition of subunits to 
actin and tubulin cytoskeletons, the intermediate filament cytoskeletons can incorporate subunits bilaterally 
along their length [81]. 
While the production of the IF proteins is controlled at the transcriptional and translational level 
and their turnover is controlled by several processes, the formation of filaments and the maintenance of the 
soluble pool of IF proteins, as well as the balance between these two, is regulated by a number of different 
post-translational modifications [31, 77, 32]. 
The majority of studies into the transcriptional regulation of GFAP and vimentin have focused on 
the alternative splicing and isoforms of GFAP [87]. Vimentin transcription and translation is thought to 
involve only one mRNA product from the vimentin gene [88]. While vimentin and GFAP both have major 
isoforms (Fig. 1-4, 1-5), GFAP is alternatively spliced into at least 8 different isoforms, with different 
developmental distributions (Table 1) [87]. Studies into the localized translation of GFAP [89] are limited, 
although there is some evidence that mRNA can be localized to astrocytic processes. Specifically, it is 
known that the GFAP alpha isoform can be found in the processes [90]. Studies about the upregulation of 
GFAP and vimentin protein in disease states usually refers to the canonical isoforms of each IF family 
member, although the isoforms are also further subjected to post-translational modifications. The major 
GFAP isoform, GFAP alpha, is the isoform of interest in this thesis. 
The intermediate filaments are subject to several types of proteolytic processing, including caspase 
and calpain cleavage, as well as ubiquitination. The calpain cleavage fragments are often seen in western 
blots, as it creates a distinct degradation pattern [92]. Caspase cleavage can cause GFAP fragments that 
promote aggregation [93]. As with many other proteins, IFs are also degraded by the ubiquitin proteasome 
pathway (UPP), and therefore ubiquitination is one mechanism by which IFs are 
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Table 1. Intermediate filament proteins in astrocytes and reactive gliosis. Modified from [91] 
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regulated in cells. Mutated GFAP interacts frequently with portions of the UPP, altering the proteasomal 
ability to degrade proteins [79]. Interestingly, this is not the only interaction between IFs and the UPP that 
can disrupt normal function. The E3 ligase responsible for tagging the IFs for proteasomal degradation is 
gigaxonin [94]. Mutations in gigaxonin cause giant axonal neuropathy, and it was found that IF degradation 
is found to be impaired in this situation [74]. Similarly, the E3 ligase parkin is the most common mutated 
protein in inherited forms of Parkinson’s Disease [95], indicating that the UPP and its normal function, 
which can be altered by dysregulated IFs, can be a factor in a number of neurodegenerative conditions. 
The intermediate filaments are subject to a large number of post-translational modifications. The 
best studied of these is phosphorylation [96], but they are also subject to ubiquitination, farnesylation, 
sumoylation, and acetylation [31]. IF proteins are also increasingly identified with the disease related PTM 
citrullination. Each of these PTMs is a form of regulation that alters the dynamics of the IF proteins in the 
cell. Studies of phosphorylation have highlighted the importance of these modifications on the function of 
the IFs. 
Phosphorylation of the intermediate filaments is very well studied, and is an important regulator of 
the assembly of the long polymeric filaments that make up the cytoskeleton [32, 77, 77, 97]. A number of 
different sites on both GFAP and vimentin are specifically phosphorylated [77, 97] (Fig. 1-4, 1-5). Two 
vimentin phosphorylation sites, Ser-38 and Ser-72, are known to inhibit the polymerization of vimentin 
when phosphorylated [32, 77]. Vimentin is phoshporylated by a number of different kinases, including 
Protein Kinase A [98, 33], Protein Kinase C [99, 33] Calcium/Calmodulin-dependent kinase II [100], 
among others. Phosphorylation in the head domain of GFAP protects against protein turnover [97]. 
Phosphorylation of vimentin at Ser-38 also sensitizes myofibroblasts to treatment with the IF targeting 
molecule WFA. In the ocular system, phosphorylation of vimentin controls the regulation of lens growth, 
as mice with vimentin phosphorylation sites mutated showed cataract like symptoms and a dramatic 
reduction in lens volume [101]. 
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Figure 1-4 Primary Amino Acid Sequence of Human Vimentin 
 
The primary amino acid sequence of human vimentin. Arginines are highlighted in yellow as potential 
citrullination sites. Several phosphorylation sites involved in filament assembly are identified (P-). 
Residues within the head domain are represented in orange, residues in the rod domain are represented in 
blue and red, and residues in the tail domain are represented in green. 
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Figure 1-5 Primary Amino Acid Sequence of Human GFAP Alpha 
 
The primary amino acid sequence of human GFAP alpha isoform. Arginines are highlighted in yellow as 
potential citrullination sites. Several phosphorylation sites involved in filament assembly are identified (P-
). R270 and R416 are recognized by antibody CTGF-1221. Residues within the head domain are 
represented in orange, residues in the rod domain are represented in blue and red, and residues in the tail 
domain are represented in green. 
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Although phosphorylation is the best studied PTM with regards to the IF proteins, citrullination  of 
the intermediate filaments is becoming acknowledged as important as an increasing number of 
neurodegenerative diseases are discovered to be associated with citrullinated GFAP and vimentin. Although 
there are relatively few studies identifying distinct effects of this PTM on GFAP and vimentin, insights 
from the modification itself, the enzymes responsible, and inhibitors of those enzymes have established 
methods to study the role of citrullination in injury and disease. 
 
 
1.7 Citrullination and the IF proteins 
 
Citrullination 
 
Citrullination, or deimination, is a post-translational modification targeting peptidylarginine. So 
named due to its original isolation from Citrullus lanatus (watermelon) [102], citrulline is a non-standard 
amino acid for which there is no corresponding tRNA [34]. It can be found as either free citrulline as a 
byproduct of nitric oxide production, or as peptidylcitrulline after conversion by a family of enzymes 
known as peptidylarginine deiminases, referred to as PADs. Citrullination of peptidylarginine is a 
hydrolytic process that requires calcium as a cofactor and creates ammonia as a byproduct (Fig. 1-6). In 
mammals, the process is carried out by five members of the same enzyme family. These are PADs1-4 and 
PAD6. For all active PADs, the level of calcium required for activity is significantly higher than 
physiological levels [103]. 
 
 
PAD enzymes 
 
The PADs are a family of five closely related and conserved enzymes that vary in their activity and 
tissue expression [34, 103]. Their presence is conserved among mammals, but other vertebrates have 
varying levels of PAD genes present [103]. They are all found in the same gene cluster [105], but have 
different tissue expression. 
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Figure 1-6. The Citrullination Reaction 
 
Citrullination is the process by which peptidylarginine is converted, through the calcium-dependent family 
of enzymes known as PADs, into peptidylcitrulline, releasing ammonia as a byproduct.  Peptidylcitrulline 
has a net neutral charge compared to the net positive charge of peptidylarginine. 
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PAD1 is found most abundant in the layers of the epidermis [106]. It has been most well studied 
in regards to its function in keratinocytes [107], where it is thought to citrullinate the keratin K1 [106], and 
is thought to play a role in psoriasis [108]. Studies into other tissues, such as spleen, kidney, and CNS 
tissues have not shown PAD1 expression, indicating its expression and function is limited to the  epidermis 
and uterus and limiting interest in models of CNS disease and injury. 
PAD2 is often considered the most broadly expressed PAD enzyme, being found in a number of 
different tissues. It was originally isolated from skeletal muscle, pancreas, and spinal cord [107]. It has 
since been identified in brain [109, 110, 19, 111], spleen and kidney [112]. PAD2 expression is also found 
in the retina, and is increased in Age-related Macular Degeneration eyes [38]. Importantly, it is known to 
citrullinate vimentin [113] and myelin basic protein (MBP) [114]. PAD2 knock-out mice [112] appear to 
show no difference in the multiple sclerosis (MS) mouse model of experimental autoimmune 
encephalomyelitis (EAE) [115] when clinical scores were compared to wild-type, even though PAD2 
appeared to be responsible for the citrullination of proteins in this system. Some controversy exists as to 
the responsibility of PAD2 in this system, as some citrullinated MBP was reported when checked by a 
second group [116]. Other methods of PAD knockdown have shown changes in this system, discussed 
below. Overexpression of PAD2 [117] caused a severe phenotype in skin, with lesions that were positive 
for a number of tumor markers, including increased IL6 and IL8 levels. Interestingly, PAD2 overexpression 
increased levels of vimentin within a skin cancer cell line as well. Similarly, it was found in a breast cancer 
cell line to have bound histones and play a role in gene regulation [118]. 
PAD3 is often found in skin and hair [106, 119], as well as in mammary glands [120] and peripheral 
nerves 121]. In the epidermis it is thought to citrullinate several proteins [106, 122, 119]. Recently, it has 
been found in human neural stem cells [123], where it was shown to inhibit neural stem cell growth and 
disrupt the vimentin cytoskeleton. This was reversed with the use of the pan-PAD inhibitor Cl-amidine. 
PAD4 is found often in immune cells, such as macrophages, lymphocytes and neutrophils. There, 
it is involved in the mass citrullination of histones to release chromatin [124]. This is possible because  
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PAD4 is the only PAD with a known nuclear localization sequence, although PAD2 has also been localized 
to nuclei [118]. Several PAD4 knockout and PAD4 low strains have been developed [112, 125, 126]. Mice 
survive, indicating that PAD4 absence is not embryonic lethal, but PAD4 may have some embryonic role, 
as PAD4 mice are thought to be slightly less viable [125]. This is supported by the fact that mice deficient 
in PAD4 show an increase in proliferation of haematopoietic cells [127]. Known to be present in a number 
of different tumor types [128, 129], and directly interact with the p53 protein [130], PAD4 likely has a  role 
in regulation of angiogenesis. A human PAD4 was originally called PAD5, but was later identified as a 
homologue of murine PAD4 [103]. This leads to the naming convention, in which there is PAD1-4 and 
PAD6. 
PAD6 is often considered inactive, as it has not been shown to have activity in vitro. It is mainly 
found in mammalian oocytes [105, 131]. Studies have shown PAD6 knockout mouse lines are embryonic 
lethal at the two cell stage [132]. mRNA has been found in a number of different tissues, but protein has 
only been reported in ovaries and oocytes [105, 133]. Like PAD1, PAD6 is not a major candidate for 
deimination in the retina. 
 
 
Targets of Citrullination 
 
While citrullination can theoretically occur on any peptidylarginine, the list of proteins known to 
be citrullinated in vivo is small. This indicates that there is likely a specific motif that the PAD enzymes 
preferably interact with, although research into this area is still limited. The list of empirically discovered 
citrullinated proteins includes several of the intermediate filaments, such as GFAP [19, 35, 134, 135], 
vimentin [19, 33, 136], desmin [33], and the keratins [122, 137]. A major target of citrullination research 
is the histones, as they can be citrullinated to control gene expression. Other proteins, such as Myelin Basic 
Protein [138] and others [122, 139, 140, 1141, 142] are also targeted by PADs.  
The citrullination of GFAP and vimentin has been identified both in vivo and in vitro [111, 35, 
135, 33]. Citrullinated proteins are upregulated in a number of different diseases. An in vitro study has 
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identified the impact of citrullination on the assembly, disassembly, and interaction of the intermediate 
filaments with phosphorylation. After incubation with PAD, there was a lack of long, filamentous structures 
and an increased presence of soluble subunits. The citrullination of the IFs also leads to the prevention of 
IF phosphorylation [33], which leads to disrupted IF assembly. Unfortunately, it is not known whether 
citrullination prevents filament formation or induces filament breakdown. 
There have been a number of studies that have identified the presence or increase of citrullinated 
proteins in the CNS in disease or injury. For instance, in Alzheimer’s [19, 134, 143], PAD2 and PAD4 are 
found in disease regions [143], citrullinated GFAP and vimentin [111] have been identified as two major 
targets, and citrullinated proteins are found in astrocytes of these patients [134]. In Parkinson’s, 
dopaminergic neurons are found to have citrullinated proteins in both cell bodies and dendrites [134]. 
Elevated PAD2 has also been seen in prion diseases [144, 145]. 
In multiple sclerosis (MS), MBP is known to be deiminated. Citrullination in MS currently has the 
most well established model concerning the pathological implications of this modification as it relates to 
disease. Interactions between MBP and lipid bilayers are partially dependent on the multiple positive 
charges on MBP, and deimination is thought to decrease this interaction [146]. While the PAD2 knockout 
mice have shown no change in the EAE model of MS [115], in either severity or onset, the use of 2- 
chloroacetamidine mentioned above showed a significant change in the disease course of EAE [116]. 
Although the insights into functional effects of citrullination on proteins are limited, the increased 
presence of these species in disease makes them an interesting target for further research. The availability 
of several different drug tools to probe roles of citrullination on IF proteins allows for further insights into 
the role of citrullination on the IF proteins and the relevance of this change to disease course.  
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1.8 Tools for probing IF Proteins 
 
Withaferin A 
 
Formerly, the IF proteins were not known to be druggable targets. The discovery that the smal l 
molecule WFA targets soluble vimentin identified for the first time a novel probe for the type III IFs [14]. 
This was achieved by developing an affinity analog of WFA, WFA-biotin, which was employed to isolate 
the binding target(s) of WFA. This study also identified that the sole conserved cysteine on vimentin is the 
covalent binding site of WFA, as observed through mass shifts from LC/MS-MS products [14]. The 
epoxide group of WFA is subject to nucleophilic attack by this cysteine, forming the covalent bond that 
can interrupt vimentin polymerization [14] (Fig. 1-7A-B, Fig. 1-8A, C). Interestingly, this finding also 
indicated the likelihood of WFA binding to other type III IF family members, as this cysteine is conserved 
within this protein family (Fig. 1-7A, red). In subsequent studies, binding to GFAP [13] was also confirmed 
through this conserved cysteine, as was another type III IF protein involved in corneal injury, desmin [15]. 
Interestingly, this conserved cysteine residue received further interest when it was shown to act as a sensor 
for divalent cations. The addition of zinc [83] is known to aid in the polymerization of filaments, and 
mutating this cysteine residue alters the initial stages of polymer formation. As will become important in 
studies of retinal gliosis, the binding of WFA to vimentin is conserved among IFs, as the same binding 
paradigm exists within GFAP (Fig. 1-8) [13]. The effects of WFA previously described were identified at 
low micromolar doses, and when the conserved cysteine is mutated, a much higher dose is required for 
potency [147]. 
The use of WFA as an anti-tumor agent predates its identification as a vimentin-targeting molecule 
[149, 150]. Although in-depth mechanisms of action for these other uses of WFA are limited, there is 
research into the pathways altered at different doses of WFA. At doses above 2 µM, WFA can have 
apoptotic effects and affects the ubiquitin proteasome pathway, as seen by a significant increase in 
ubiquitinated proteins in human umbilical vein endothelial cells (HUVECs) when treated with 5 µM WFA 
[151]. Another well established pathway that can be affected by WFA is the NF-kB pathway, 
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Figure 1-7. Conservation of Cysteine Residue and WFA binding Residues in Vimentin 
 
(A) Sequence within rod 2B domain in multiple vertebrate species revealing the conservation 
among a number of species. In red are the residues with which WFA interacts; cysteine (covalently), 
Glutamine and Aspartic Acid (non-covalently). (B) Coiled-coil parallel dimer of vimentin with Head, Tail 
and Rod (linker and coil) regions outlined. Modified from [148, 14] 
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Figure 1-8. Structure and interaction of WFA with GFAP and Vimentin 
 
(A) Chemical structure of Withaferin A (WFA). (B) Ribbon Diagram Interaction of WFA with GFAP 
tetramer, including interaction of WFA epoxide group with the conserved cysteine of GFAP.  (C) Diagram 
of WFA in binding cleft of vimentin. Modified from [14, 13] 
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known to be associated with optic nerve head astrocytes in glaucoma [152]. WFA inhibits NF-kB at a 1 
 
µM dose in HUVECs, through alteration of the normal degradation of phosphorylated IkB. The complex 
interaction of WFA in different systems, including those related to ocular health, and at varying doses, 
highlight the potential use of WFA in these systems in conjunction with other, known inhibitors [153]. 
Antibodies Recognizing Citrullinated Proteins 
 
The early methods to recognize citrullination either relied on PAD activity or identification of a 
modified form of peptidylcitrulline, which could then be probed in more conventional means. An excellent 
review of previous methods was recently published [154], and the focus here will be on two antibodies to 
identify citrullinated species, F95 and CTGF-1221. 
The F95 antibody is a mouse monoclonal IgM raised against a deca-citrullinated peptide [155], 
linked to keyhole limpet hemocyanin. It has been used for identification of citrullinated proteins in 
Alzheimer’s [134], Multiple Sclerosis [35], and an experimental model of hypoxia [156]. Its initial 
confirmation was through the ability to bind highly citrullinated forms of MBP by ELISA, and has been 
subsequently confirmed through immunoprecipitation, mass spectrometry, and the use of a number of 
different inhibitors [157, Chapter 2-3]. Increased citrullination of GFAP leads to decreased antigenic 
reactivity to GFAP [19] antibodies. This led to the development of specific citrullinated GFAP antibodies. 
One of these antibodies, CTGF-1221, is raised against human GFAP citrullinated at R270 and R416 
(corresponding to R267 and R413 in mouse) [19]. This antibody was capable of recognizing recombinant 
human GFAP in vitro after exposure to PAD enzymes, confirmed by mass spectrometry and western 
blotting. The use of these two antibodies, in both immunohistochemistry and proteomic analysis by SDS- 
PAGE has allowed for a greater probing of the function of IFs in a number of different systems. 
PAD Inhibitors 
 
In recent years, the ability to target and inhibit the PAD enzymes has become a subject of 
increasing interest, given the prevalence of this modification in disease. While insight into the functional 
effects that citrullination has on proteins has not advanced far, the identification and improvement of 
inhibitors has become a well-studied field. 
27 
 
Initially, taxol (paclitaxel) was used to inhibit PADs [158], and it showed an effect when used in 
the EAE model [159]. This is complicated by the fact that taxol not only blocks PADs, but mainly alters 
the dynamics of microtubules. Later, it was found that 2-chloroacetamidine, which was somewhat similar 
to known substrates, was a useful inhibitor [160], altering disease course in EAE [116]. A year later, an 
improved inhibitor called F-amidine was developed using a similar concept, namely that a compound that 
could covalently bind to the active site cysteine would strongly inhibit PAD activity. After this, a new 
inhibitor, Cl-amidine, was developed [161]. Cl-amidine has been the most widely used inhibitor so far, 
seeing improvements in several clinical models [162, 163, 164, 165, 166]. 
While the separate PAD enzymes have different responses for each of the different inhibitors, more 
recent work has looked into specific inhibitors for the different enzymes. Derivatives of Cl- and F- amidine 
are effective PAD3 inhibitors [167]. PAD4, as the enzyme that is known to be involved in a wide variety 
of different processes, has garnered the most interest as a target of inhibition. A novel high- throughput 
screen has identified streptonigrin, an antitumor antibiotic, as an extremely effective and selective inhibitor 
of PAD4 activity [168] that, like Cl-amidine, is irreversible. This inhibitor represents a useful research tool, 
although its off-target effects are likely to limit potential as a therapeutic [169, 170]. 
 
 
1.9 Conclusion 
 
In a system such as the mammalian retina, which does not normally regenerate but is subject to 
scarring and fibrosis, the regulation of the IF proteins is a major influence on tissue health. Recent studies 
have highlighted the importance of the soluble forms of two IF proteins, GFAP and vimentin, on scarring 
and retinal health. One of the PTMs that regulate these filaments is the relatively understudied modification 
of citrullination. Citrullination is increasingly being recognized as a disease related process, with 
citrullinated GFAP and vimentin being found in a number of neurodegenerative diseases.  
The roles of GFAP and vimentin in scarring remain a clinically important issue that remains a 
challenge. The identification of injury and disease-related mechanisms of soluble GFAP and vimentin 
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regulation is a key step toward understanding how one may attempt to improve recovery in pathological 
conditions. This thesis work hypothesizes that citrullination is an injury-induced response to injury in the 
eye, and that it is occurring to the IF proteins GFAP and vimentin. Further, this citrullination can be targeted 
in the retina by a number of different molecules in full organ and tissue systems. 
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2.1 Abstract 
  Purpose:  A  hallmark  of  retinal  gliosis  is  the  increased  detection  and  modification  of  the  type  III  
 
intermediate filament (IF) proteins vimentin and glial fibrillary acidic protein (GFAP). Here we have 
investigated vimentin and GFAP in Müller glia in a mouse model of alkali injury, focusing on the post - 
translational modification of citrullination. 
Methods: Mice were injured by corneal exposure to 1.0 N NaOH and eyes were enucleated at different  
 
time points post injury. Levels of soluble and cytoskeletal forms of IF proteins and citrullination were  
measured by western blots. Citrullinated GFAP was identified by immunoprecipitation followed by 2- 
dimensional isoelectric focusing-poly acrylamide gel electrophoresis western blotting using a specific 
antibody that recognizes citrullinated-GFAP. Vimentin, GFAP and citrullinated proteins were localized in 
the retina by immunohistochemistry (IHC). Drug treatments were investigated in retinal explant cultures 
of posterior eye-cups obtained from mouse eyes that were injured in vivo. 
Results: We report that detection of GFAP in injured retinas increased over a period of 1 to 7 days, 
 
showing increase levels in both soluble and cytoskeletal forms of this IF protein. The global level of 
citrullinated proteins was also induced over this time period, with low-salt buffer extraction showing the 
most abundant early changes in citrullination. Using IHC, we found that GFAP filaments assembled at 
Müller glial end feet, growing in size with time through the inner layers of the retina between 1 to 3 hours 
post injury. Interestingly, over this early time period, levels of soluble citrullinated proteins also increased 
within the retina as detected by western blotting, coincident with localization of the citrullinated epitopes 
on growing GFAP filaments and existing vimentin filaments by 3 hours post injury. Taking advantage of 
the in vivo injury model to promote a robust gliotic response, posterior eye-cups from 7-day post-injured 
eyes were treated in explant cultures with the peptidyl arginine deiminase inhibitor Cl-amidine, which was 
found to reduce global citrullination. Surprisingly, the detection of injury-induced high molecular weight 
GFAP species containing citrullinated epitopes was also reduced by Cl-amidine treatment. Using a low dose 
of the potent type III IF drug withaferin A (WFA), we showed that Cl-amidine treatment in combination 
with WFA reduced global protein citrullination further, suggesting that GFAP may be a key component of 
pathological citrullinated targets. 
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Conclusions: Our findings illuminate citrullination as a potential novel target for trauma-induced  retinal 
 
gliosis. We also propose that strategies for combining drugs targeting type III IFs and citrullination may 
potentiate tissue repair, which is an idea that needs to be validated in vivo. 
 
 
2.2 Introduction 
 
Gliosis is a pervasive and complex process that occurs in many central nervous system (CNS) 
disorders and after traumatic injury, where astroglial cells become reactive, proliferate and undergo 
hypertrophy [171, 172]. A major hallmark of reactive gliosis is the overabundance of the type III 
intermediate filament (IF) proteins vimentin and glial fibrillary acidic protein (GFAP). When stimulated 
by stress signals or injury, radial Müller glia, which span the entire width of the retina, initiate reactive 
gliosis by increasing levels of GFAP. Soluble tetrameric precursors of GFAP, along with vimentin, co- 
polymerize into long filamentous forms that create an elaborate cytoskeleton network [8]. Notably, 
heightened detection of GFAP and vimentin filaments is found in several major human retinal diseases 
[173, 174, 55]. As such, the pathological overabundance of GFAP and vimentin in Müller glia can drive 
the formation of scar tissue [175, 176]. Scar tissue exerts tractional forces on retinal membranes, distorting 
underlying vital cellular structures for which surgery is currently the only treatment option [177]. 
Corroborating such a pathological role for overabundance of type III IFs in neurodegeneration, the 
deficiency of vimentin and GFAP in mice is protective in several stress-related and injury contexts [178, 
171], but the tissue fragility due to complete lack of filaments underscores the importance of these type III 
IFs in normal structural function of Müller glia [24]. The ability to regulate glial reactivity to promote 
wound healing and halt destructive aspects of glial overactivation could benefit from a greater 
understanding of how vimentin and GFAP are regulated during the injury-repair process. 
 
 
Vimentin and GFAP are both regulated by multiple post-translational modifications (PTM) [33, 
179, 180, 181, 182]. Among these is the PTM citrullination, also known as deimination. Citrullination   is  
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the calcium-dependent transformation of arginine residues on proteins. This reaction is carried out by the 
enzyme family called peptidyl-arginine deiminases, or PADs. There are five known PAD isoforms in the 
mammalian genome, PAD1 to 4, and PAD6 [34]. Citrullinated GFAP and vimentin have been observed  in 
the brains of Alzheimer’s patients [111], while citrullinated GFAP is found to accumulate in the brains of 
Multiple Sclerosis (MS) patients [36]. In the experimental autoimmune encephalomyelitis (EAE) model of 
MS, a small molecule inhibitor of PAD activity was able to rescue diseased mice from clinical EAE [116]. 
Increased citrullination has also been recently reported in the retina and optic cup of age- related macular 
degeneration (AMD) donor tissues [38], as well as in the glaucomatous optic nerve [39] and in astrocytes 
exposed to increased ocular pressure [183]. While there have been recent insight into the mechanics of 
retinal injury [184, 185, 62, 186], the use of PAD inhibitors has only recently been explored in an 
experimental model of neurotrauma [187]. In that study, effective early downregulation of protein 
citrullination within hours of injury that is protective highlights the importance of molecular events that 
occur during the early hours following CNS injury [187]. Previous studies have suggested that citrullination 
may affect the formation of filaments by blocking phosphorylation sites or induce the collapse of insoluble, 
filamentous type III IFs [33, 188]. The in vitro investigation of these type III IFs has provided the insight 
that citrullination impacts type III IF polymerization/depolymerization steps, but the physiological  
relevance of this PTM of type III IF proteins in retinal gliosis remains unknown. 
Using an alkali injury model, we previously showed that the small molecule withaferin A (WFA) 
targets vimentin and GFAP in Müller glia during retinal gliosis in vivo [13, 46]. WFA targets type III IFs 
via binding to a highly conserved rod 2B domain that is common to this class of IF protein [13, 151, 14, 
15]. Given its potent effects targeting soluble forms of IFs, WFA reduces the proliferative response of 
Müller glial cells in gliosis, and ultimately, also perturbs the filament structure of IFs [153]. Here we have 
exploited the alkali injury model to investigate whether citrullination occurs during retinal gliosis. We show 
for the first time that citrullinated modified forms of vimentin and GFAP filaments are detected very early 
after injury. Using the alkali-injured mouse eyes in an explant culture model [13], we have also established 
that this system can robustly enhance citrullination ex vivo, providing a convenient method to 
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investigate the signaling axis that links reactive gliosis with citrullination using pharmacological inhibitors 
of citrullination and type III IFs. 
 
 
2.3 Materials and Methods 
Ethics Statement 
All animal experiments were conducted in accordance with procedures approved by IACUC committee of 
the University of Connecticut Health Center. Mice were housed in specific pathogen free cages in 
designated laboratory animal housing facilities. 
 
 
Drug Treatments in Retinal Explant Culture System 
 
N-a-benzoyl-N5-(2-chloro-1-iminoethyl)-L-Orn amide (Cl-amidine) was purchased from EMD Millipore 
(#506282, Billerica, MA). WFA was purchased from Chromadex (Santa Ana, CA). 
 
 
Mice and Ocular Injuries 
 
129S6/SvEVTac mice were purchased from Taconic (Hudson, NY) and bred in house. Over 100 mice of 
approximately 2-3 months of age were used in this study. Corneal alkali injuries were performed in 
129S6/SvEVTac (Taconic, Hudson, NY) mice of either sex as previously described [13] with a minor 
modification. Mice were given an intraperitoneal (i.p.) injection of Ketamine/Xylazine, and corneas were 
anesthetized with proparacaine eye drops. A 1 µl drop of 1N sodium hydroxide was then applied directly 
to the central cornea for 45 seconds. The 1N alkali strength is widely used in experimental mouse models  
[189] and has clinical relevance [190]. Following injury, the eye was immediately flushed extensively with 
sterile phosphate buffered saline (PBS) solution. The corneal epithelium was gently removed using a Tooke 
knife, and eyes were then treated topically with atropine, followed by tobramycin and erythromycin. For 
time course studies, injured mice were treated daily with topical applications of tobramycin  and  
erythromycin  for  3  days  post-injury  and  humanely  sacrificed  by  CO2  inhalation at 
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different times. Equal numbers of male and female mice were pooled in experiments, and all mice 
underwent bilateral alkali injury. 
 
 
Retinal Dissections 
 
Mouse eyes were enucleated immediately after sacrifice as previously described [13]. Eyes were placed 
into ice-cold PBS + Antibiotic/Antimycotic (A/A) solution until dissection on ice. 
 
 
Posterior Eye Cup Explant Culture 
 
Enucleated eyes from 7 days post-injury mice were dissected under sterile conditions to separate the 
posterior eye-cup from the anterior aspect. The posterior eye-cups, which contain the neural retina, retinal 
pigment epithelium, choroid and sclera [13], were briefly rinsed in PBS and then distributed 1 eye cup per 
well  into  750  ml  DMEM/F12  (Gibco,  Waltham,  MA)  medium  +A/A  (Invitrogen,  Waltham,   MA) 
solution, +10% fetal bovine serum (FBS; Atlanta Biologicals, Flowery Branch, GA) in a 24-well culture 
dish. The eye-cups were placed in a 5% CO2 incubator at 37 
o
C and subject to drug treatments. Fresh batches 
of either Cl-amidine or WFA was replenished daily for a treatment period of 3 days in DMEM cell culture 
medium containing 10% FBS or left untreated. DMSO was used as vehicle in similar pilot  
experiments along with Cl-amidine concentration studies to identify an effective concentration for 
treatments. 
 
 
Protein Extraction from Retinal Samples 
 
Three mouse eye-cups were placed in ice-cold soluble buffer (20 mM Tris buffer, 200 mM NaCl, 1% NP- 
 
40) supplemented with a proteinase inhibitor cocktail (Roche, Indianapolis, IN) and tissue was minced into 
pieces on ice. Samples were left on ice for 45 minutes and then spun at 14,000 RPM for 5 minutes at 4 
o
C. 
The supernatant was removed and labeled as the “soluble” fraction (containing soluble forms of   IF  
proteins),  while  the  pellet  was  placed  into  1:3  diluted  β-mercaptoethanol:Laemmli  buffer  to extract 
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cytoskeletal forms of IFs and spun down at 14,000 RPM for 5 minutes at 4 
o
C. This protein extract was 
labeled as the “insoluble” cytoskeletal fraction. Both soluble and insoluble fractions were then passed 
repeatedly through a 26-gauge needle 10 times to shear DNA. 
 
 
Immunostaining 
 
Unfixed eyes were first frozen in OCT (Tissue-Tek, Radnor, PA) at -80 
o
C, before being cut on a cryostat 
at -24 
o
C. Sections were cut at 10 or 15 µm thickness, attached to Superfrost slides and stored at -80 
o
C 
until used. Slides were air dried for 30 minutes and then fixed in ice-cold methanol/acetone (5 min/1 
min). Fixed slides were washed in PBS 3 times for 5 minutes, and then primary antibody was added in 
Dako background reducing solution (Dako, Glostrup, Denmark) at the specified concentration. Slides were 
incubated with primary antibody for 3 h at 37 
o
C and then either washed directly or moved to 4 
o
C overnight 
for further incubation and then washed 5 times for 10 minutes afterwards. Slides were then incubated with 
secondary antibodies at specified concentrations overnight (15 h) at room temperature   in  
the dark, and subsequently washed 5 times for 10 minutes prior to imaging. 
 
 
 
Western Blotting 
 
Bicinchoninic Acid Assay (Pierce, Waltham, MA) was used for quantification of protein. Protein samples 
were boiled 95-100 
o
C for 5 to 10 minutes in Laemmli buffer and then loaded on 4-20% Tris-HCl SDS- 
polyacrylamide gels (Bio-Rad). Proteins were transferred onto a 0.2 µm PVDF membrane (Bio-Rad, 
Hercules, CA). Membranes were blocked in 5% milk in 1X Tris Buffered Saline + Tween (TBST) for 1 
hour at room temperature, then incubated with primary antibody for 1 hour at room temperature or 
overnight at 4
o 
C. Membranes were washed 3 times for 15 minutes, then incubated with secondary antibody 
for 45-60 minutes at room temperature. Membranes were washed 4 times for 15 minutes and 
developed with Enhanced Chemiluminescence (ECL; Bio-Rad) solution. To normalize for protein loading, 
membranes were stripped in 10X Tris-Glycine-SDS buffer for 30 minutes at RT, then probed  as 
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above with either glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or β-actin antibodies. All figures 
are shown with corresponding GAPDH or β-actin control beneath. 
 
 
Antibodies 
 
Primary antibodies used in the experiments included: rabbit polyclonal anti-GFAP (Abcam, Cambridge 
UK, 7779 1:4,000 WB, 1:500 IHC; Abcam 7260 1:20,000 WB, 1:500 IHC), mouse-IgM monoclonal F95 
(anti-peptidyl-citrulline antibody, Millipore MABN328, 1:500 WB 1:200 IHC), rabbit polyclonal  GAPDH 
(Santa Cruz, Dallas TX sc25778 1:500 WB), rabbit polyclonal vimentin (Abcam ab45939 1:200 IHC), 
mouse monoclonal β-actin (Sigma, St. Louis, MO A5441 1:1,000 WB), mouse β-tubulin (Santa Cruz 
sc55529 1:1000 WB) and citrullinated-GFAP [69] (CTGF-1221, 1:1000); Secondary antibodies were 
Santa Cruz goat anti-rabbit IgG HRP (sc-2301 1:1000 WB), goat anti-mouse IgG HRP (sc-2302 1:1000 
WB), goat anti-mouse IgM HRP (Jackson ImmunoResearch, West Grove, PA #115-035-075 1:5,000 WB) 
goat anti-mouse IgM 488 (Invitrogen A21042 1:500 IHC), goat anti-rabbit IgG 488 (Invitrogen A11008 
1:500 IHC), goat anti-rabbit IgG 594 (Invitrogen A11012 1:500). 
 
 
Immunoprecipitation and 2-Dimensional PAGE separation 
 
Citrullinated proteins were immunoprecipitated using the F95 antibody using protein-L agarose bead 
chromatography. In brief, on day 1, 500 µl protein-L agarose beads (Sigma-Aldrich) were washed 2 times 
for 5 minutes and once for 30 minutes in soluble buffer with phenylmethylsulfonyl fluoride (1 mM PMSF), 
sodium fluoride (5 mM NaF), sodium orthovanadate (1 mM Na3VO4), protease inhibitor cocktail and 
dithiothreitol (1 mM DTT). Following this wash step, the final volume of protein-L beads was brought to 
500 µl with this soluble buffer. F95 antibody was added at 1:50 and incubated with washed 
protein-L beads overnight on a rotator at 4
o 
C. On day 2 this bead-antibody mixture was spun down at 
 
3,000xg for 2 minutes. This mixture was then washed 2 times for 5 minutes in soluble buffer at half 
concentration (10 mM Tris, 100 mM NaCl, 0.5% NP-40, 0.5 mM PMSF, 2.5 mM NaF, 0.5 mM  Na3VO4 
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0.5 mM DTT) and once for 30 minutes, spun down at 3000xg for 2 minutes between washes. Posterior eye-
cups from 8 injured and 8 uninjured eyes were separately solubilized in 120 µl each of the original soluble 
buffer and treated as soluble protein. Once extracted, 100 µ1 of the soluble fraction of protein was added 
to bead-antibody mixture, and half concentration of soluble buffer added to 500µl final volume. This 
mixture was then incubated on a rotator overnight at 4
o 
C. On day 3, this bead-antibody-sample 
mixture was then spun down at 3,000xg for 2 minutes. Supernatant from this spin was removed. Beads  
 
were then washed with half concentration of soluble buffer 4 times for 5 minutes. After the final wash, 
soluble buffer was added to final volume of 500 µl. 400µl of this mixture was spun down for 3,000xg for 
2 minutes, and supernatant was removed. This bead mixture was resuspended in 160µl reconstitution  
buffer (8 M urea, 2% CHAPS, 50 mM DTT, 0.2% Bio-Lyte 3/10 ampholytes and Bromophenol Blue, from 
Bio-Rad ReadyPrep 2D Starter Kit, cat #163-2105). Samples were then heated to 95-100
o 
C for 10 minutes. 
After boiling, the sample was spun down for 1 min at 14,000 RPM. Supernatant was  considered 
“bound” fraction. 
 
 
After immunoprecipitation, 160 µl bound fractions were added to pH 4-7 Immobilized pH Gradient 
(IPG) strips (Bio-Rad #163-2015) and underwent passive rehydration for 1 hour followed by active 
rehydration at 50 volts for 14 hours in Bio-Rad Protean IEF Cell (Bio-Rad #165-4000). After rehydration, 
IPG strips underwent isoelectric focusing per the manufacturer’s instructions (Bio-Rad #163- 2105). IPG 
strips were then run on a 4-20% gradient polyacrylamide gel (Bio-Rad #567-1091). Following PAGE 
separation, protein was transferred to PVDF membrane, blots blocked in 5% milk in 1X TBST,  and probed 
with primary antibodies as described. Uninjured and injured samples from the same experiment were run 
in parallel. 
 
Confocal Microscopy 
Immunofluorescent images were taken on a Confocal Microscope (Zeiss LSM 780, Zeiss, Oberkochen, 
Germany) on individual planes isolated from xyz stacks of retinal sections with 15µm thickness. Final 
images were 4-frame averages taken at 20X or 63X magnification that were acquired randomly from retinal 
sections. Laser intensity was maintained the same across all images. 
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Statistical Analysis 
 
Each sample for western blot analysis contained pooled protein extracts from three separate mouse eyes, 
and entire injury experiments were repeated three times to obtain quantitative results. Data represented 
were the mean of three experiments (n=3) normalized to GAPDH or β-actin. The data was analyzed to 
obtain the means and ± standard deviation (SD) using t-tests, with a difference of p <0.05 considered 
statistically significant. 
 
 
2.4 Results 
 
Citrullination is an early injury response in the retina 
 
We modified a previously established mild alkali injury model where induction of retinal gliosis becomes 
prominent by day 7 post-injury, as characterized by increased detection of vimentin and GFAP in Müller 
glia [13]. Extending our prior findings to earlier time points (days 1, 3 and 7 post-injury), we found there 
was a temporal increase in GFAP immunoreactivity that was produced after injury. Notably, the soluble 
protein extracts reveal the increased levels of GFAP (Fig. 2-1A) and vimentin (Fig. 2-1B). We assessed 
injured retinal tissues to determine the time-course of gliosis-associated citrullination in the retina. We 
found that there was an immediate induction of citrullinated protein species that were found in the soluble 
fraction starting at 1 day post-injury (Fig. 2-1C). This sustained induction of citrullination lasted through 7 
days. In comparison, citrullinated species in the soluble fraction of proteins were very low in the 
uninjured eye (Fig. 2-1C, lane 1). By day 1 after injury, citrullinated proteins were visualized at a variety 
of molecular weights, with distinct bands at 50 kDa and 75 kDa and a pattern of high molecular weight 
bands between 150 and 250 kDa. Overall, the increased citrullination of proteins in the soluble extracts  
closely paralleled the increase in the major 50 kDa GFAP protein species and its several lower molecular 
weight cleaved forms [46] produced over this time period (Fig. 2-1A; Fig. 2-1B ~75 kDa, arrowhead; Fig. 
2-1C ~50 kDa, asterisk). The distribution of citrullinated proteins within the high molecular weight range 
in the soluble fraction was also altered over the time course of injury, with a 250 kDa band increasing over 
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Figure 2-1. Detection of soluble citrullinated proteins after ocular alkali injury. 
 
Western blot analysis of soluble protein extracts from retino-choroidal tissues of uninjured eyes (lane 1) 
and mouse eyes injured in vivo for 1, 3, and 7 days. Blots were probed for GFAP (A), vimentin (B) and 
citrullinated proteins (C), followed by GAPDH antibodies for loading control. The major 50 kDa band (C, 
asterisk), and 75 kDa band (C, arrowhead), along with minor high molecular weight bands over 150 kDa 
to 250 kDa bands (bracket) were identified at all stages post-injury when examined for citrullination. GFAP 
antibody reactive species were detected between 37 kDa and 50 kDa (A). Uninjured and injured eyes exhibit 
vimentin reactivity at isoforms ranging from 37 to 55 kDa (B). Bar graphs (D, E) represent quantification 
of the 75 and 50 kDa citrullinated species, respectively. Each sample contained tissue extracts  pooled  from  
3  retinas  from  which  soluble  protein  was  extracted  as  described  in Methods. 
Experiments were repeated three times (n=3), *=p<0.05, #=p<0.01 by t-test 
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time while the 200 and 150 kDa bands leveled off between days 3 and 7, post injury. 
When we assessed the insoluble fraction of retinal lysates using the F95 monoclonal antibody 
multiple bands reactive for citrullinated proteins were also present in the insoluble extracts of both injured 
and uninjured eyes (Fig. 2-2). In particular, the presence of a 75 kDa citrullinated protein was slightly 
increased by 3 days after injury (Fig. 2-2A; arrowhead, ~75 kDa; Fig. 2-2B). While the 50 kDa species 
increased early after injury and then decreased by 7 days, the changes in this species are not significant. (Fig. 
2-2A, asterisk, ~50 kDa; Fig. 2-2C). On the other hand, GFAP in the insoluble fraction shows an increase 
through 7 days (Fig. 2-2D), while vimentin increases through 3 days and returned to uninjured levels at 7 
days (Fig. 2-2E). Altogether, our findings showed that there were global changes in protein citrullination 
that occurred after injury and these reflect temporal progression with the early onset of retinal gliosis in this 
model. 
 
 
Multiple isoforms of GFAP are citrullinated in the mouse retina 
 
We next wanted to characterize the GFAP isoforms that become citrullinated after retinal injury. This 
proved to be a challenge for two major reasons. First, soluble tissue extracts from 7 day-injured retinas 
identified at least 28 distinct GFAP-antibody reactive spots by two-dimensional (2D) isoelectric focusing- 
polyacrylamide gel electrophoresis (IEF-PAGE) and western blot analysis (Fig. 2-S1). This suggested the 
likelihood of a complex citrullinated GFAP pattern. Second, a recent finding showed that with increasing 
levels of citrullination on GFAP its binding to the GFAP antibody is increasingly lost [19], highlighting  
the difficulty of identifying these modified GFAP isoforms by either F95 or GFAP immunoprecipitation. 
Fortunately, a novel antibody raised against citrullinated GFAP (CTGF-1221) that recognizes this PTM at 
positions R270 and R416 in humans (R267 and R413 in mice, respectively) was developed in that study 
 [19]. Using immunoprecipitation, citrullinated proteins from the soluble pool of 7-day injured retinas 
were affinity isolated using the F95 antibody and subjected to IEF-PAGE. These protein blots were then 
subjected to incubation with the CTGF-1221 antibody to detect citrullinated GFAP. 
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Figure 2-2. Detection of insoluble citrullinated proteins after ocular alkali injury. 
 
Western blot analysis of insoluble proteins from retino-choroidal tissues from uninjured and injured mouse 
eyes as described in Figure 1. Gel blots were probed sequentially for citrullinated proteins (F95), GFAP 
and vimentin. Corresponding GAPDH loading controls are located beneath each blot. Citrullinated proteins 
were detected in all insoluble fractions (A) with major bands detected at 75 kDa (A, arrowhead) and at 50 
kDa (A, asterisk), with minor bands over the high molecular weight range between 150 kDa and 250 kDa 
(bracket). Bar graphs (B, C) represent quantification of the 75 and 50 kDa citrullinated species, respectively. 
GFAP isoforms were detectable at all time points below 37 kDa and 50 kDa (D). A 55 kDa vimentin 
isoform was detectable at all time points (E). Each sample contained tissue extracts pooled from 3 retinas 
from which protein that not solubilized in low-salt buffer was extracted as described in Methods. 
Experiments were repeated three times (n=3), *= p <0.05. 
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Figure 2-3. Detection of Citrullinated GFAP in uninjured and injured retinas 
 
Two-dimensional IEF-PAGE separation of soluble proteins from uninjured and 7 day injured retinao- 
choroidal tissues immunoprecipitated for citrullinated proteins (F95 antibody) and western blotted first 
with CTGF-1221 antibody (A, B) and subsequently with the F95 antibody (C, D). Blots of the injured 
retinas probed with the anti-citrullinated GFAP antibody (B) showed lower relative abundance of ~50 
kDa protein species compared to 75 kDa species when re-probed with F95 antibody (D). 
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As a comparison, soluble fractions from uninjured retinas were also analyzed by IEF-PAGE, and 
western blotted with the CTGF-1221 antibody. . The 2D-immunoblots from uninjured retinas probed 
with the CTGF-1221 antibody did not identify reactive species (Fig. 2-3A). The 2D-immunoblots from 
injured retinas probed with the CTGF-1221 antibody revealed intense reactivity at the anticipated 50-
52 kDa size for citrullinated GFAP species (Fig. 2-3B). The major immunoreactive region showed two 
closely spaced 50- 52 kDa overlapping species distributed over isoelectric points of 5.25 and 5.6 (Fig. 
2-3B, box). A second region between isoelectric points of 4.50 to 5.00 was detected, with additional 
minor species being detected between the two boxed regions (Fig. 2-3B, box). These two boxed-
regions correspond to the ~50 kDa broad band that was observed by one-dimensional western blots 
with the F95 antibody (Fig. 2-1A). To detect all the citrullinated species the blots were re-probed with 
the F95 antibody. The uninjured retinas showed broad immunoreactive diffuse spots at 75 kDa and 
between 37 and 50 kDa with isoelectric points between 5.5 and 6.0 (75 kDa, Fig. 2-3C) and 4.5 to 5.75 
(37-50 kDa, Fig. 2-3C). This detection is likely due to the immunoprecipitation with F95 antibody. 
Similarly, the blot from injured retinas displayed F95 immunoreactivity at a range of molecular weights 
and isoelectric points (Fig. 2-3D, boxed regions). Specifically, an intensely labeled broad region 
located around 75 kDa and less intensely labeled broad region around 50 kDa closely resembled the 
immunoreactive bands seen in Fig. 2-1A (arrowhead, asterisk respectively). The multiple 75 kDa 
species were distributed between isoelectric points from 4.50 to 5.00 and 5.25 to 5.75, whereas those 
at 50 kDa species of low abundance and distributed between isoelectric points from 4.50 to 5.00 and 
between 5.25 to 5.60 (Fig. 2-3D, boxed regions). We also identified a region between 37 kDa and 50 
kDa that contained immunoreactive species between isoelectric points of 5.25 and 5.60. The protein 
blots of soluble extracts from 7 day injured retinas probed for native GFAP (Fig. 2-S1) when overlaid 
on 2D IEF western blot of extracts subjected first to F95 immunoprecipitation  and  then  2D  separation  
revealed  that  citrullinated  GFAP  species  (detected  by CGTF-1221 antibody) migrate differently 
from native GFAP species (Fig. 2-S2). These data reveal that the injured retina retains considerable 
amount of GFAP in the soluble fraction as diverse citrullinated species. 
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Citrullination occurs on type III IFs within Müller glia 
 
We next investigated the spatial and temporal patterns of citrullination upon injury during the early 
time points of tissue repair in relationship to vimentin and GFAP staining. The uninjured retina 
displayed minimal F95 reactive species in the inner retina, while the outer plexiform layer was absent 
of any staining (Fig. 2-4 A-C). Long filamentous structures and co-localization with F95 reactive 
species were observed in Müller glia as early as 1 hour after injury (Fig. 2-4 D-F, asterisk). We 
observed both a punctate staining starting at the ganglion cell layer (GCL) through the inner plexiform 
layer (IPL) and inner nuclear layer (INL) as well as filamentous structures throughout the inner retina. 
Immunoreactivity was also observed in the OPL (Fig. 2-4; D-F). Interestingly, filamentous structures 
that were interspersed with both GFAP positive and F95 positive regions were seen in Müller glia at 3 
hours (Fig. 2-4G-I, brackets), but not at 1 day (Fig. 2-4H-L), and seen again by 3 days (Fig. 2-4M-O, 
brackets) post injury. These filaments are visually different from co-localization of GFAP and F95 
immunostaining, and are referred to as “interspersed” filaments. These interspersed filaments show 
distinct regions of F95 immunoreactivity alternating with regions of GFAP immunoreactivity along 
extended filamentous structures. Filaments exhibiting co-localization of GFAP and F95 persisted 
through 3 hours after injury (Fig. 2-4 G, I asterisks), while long filament-like structures of citrullinated 
proteins (Fig. 2-4H, I, arrowheads) were observed absent of GFAP. At 1 day after injury, there was a 
strong detection of F95 positive species within the INL. Non-continuous filaments were observed 
extending below an enlarged astrocyte (Fig. 2-4L, asterisk). Strong co-localization of GFAP staining 
with F95 immunoreactivity was observed in the GCL and IPL at 3 days after injury (Fig. 2-4 O, 
asterisk). Long GFAP filaments were established by 3 days after injury, and co-localization of GFAP 
and F95 staining occurred near the border of the GCL and IPL. With time, nuclei in the GCL displayed 
F95 immunoreactivity, and GFAP positive processes extended into the vitreous, indicating a separation 
from the inner limiting membrane (ILM; Fig 2-S3A-B). Full-length vimentin filaments (Fig. 2-5) were 
observed throughout the layers of the retina in the uninjured Müller glia (Fig. 2-5 A-C), as has been 
previously reported [13, 17]. 
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Figure 2-4. Citrullination of GFAP filaments after injury. 
 
Cryosections from uninjured and injured eyes were stained with GFAP (red) and F95 (green) and nuclei 
stained with DAPI (blue). Sections were examined under confocal microscope at 20X at an uninjured  state 
(A-C), 1 hour (D-F), 3 hours (G-I), 1 day (J-L) and 3 days (M-O) post injury. Extensions of GFAP staining 
beyond nuclei of the GCL are marked by an arrow (F). Co-localization of GFAP and F95 antibodies are 
marked by asterisks (F, I, L, O). Interspersed regions of GFAP and F95 reactivity is outlined in brackets (I, 
O). GFAP negative, F95 positive filaments are marked by arrowhead (I). GCL, ganglion cell layer; IPL, 
inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer. 
(Scale bar = 100 µm) 
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As early as 1 hour after injury,    vimentin    immunoreactivity    within    the    outer    layers    of     the     
retina     was diminished, while co-localization with F95 reactive species was observed in the IPL (Fig. 2-
5 D-F, asterisk). As with GFAP staining, filaments interspersed with both vimentin positive regions and 
F95 positive regions were seen predominantly in the IPL, extending into the GCL (2-5F, brackets). Three 
hours after injury, co-localization of vimentin staining and F95 immunoreactive species was observed (Fig. 
2-5 G-I, asterisk), and filaments extended beyond nuclei in the GCL into intravitreal space (Fig. 2- 5I, 
arrows). One day after injury filamentous vimentin was observed throughout the layers of the inner retina, 
with nuclear F95 staining (Fig. 2-5-J-L). The extension of vimentin staining into the vitreous was also 
observed at 3 days post-injury (Fig. 2-5O, arrow; Fig. 2-S3C-D). Long vimentin filaments also became 
interspersed with F95 immunoreactive species by 1 hour (Fig. 2-5F, brackets), into 3 hours (Fig. 2-5I, 
brackets) and at 3 days (Fig. 2-5O, brackets) post-injury. Müller glia recovered full filament structure by 
1 and 3 days after injury, but also displayed perinuclear staining of both vimentin and citrullination in the 
OPL (Fig 2-5O, arrowhead). Of note is the border between the OPL and the INL, which displayed a strong 
abundance of vimentin and F95 immunoreactivity at 1 and 3 days, respectively. The rearrangement of these 
filaments and their citrullination highlights the importance of examining early and immediate responses to 
injury. 
We also examined the pattern of citrullination at higher magnification. The distinct pattern 
observed previously was clearly visible, as both GFAP (Fig. 2-6) and vimentin filaments (Fig. 2-7) 
appeared less organized at 3 hours (A-C) than at 3 days (D-F). GFAP filaments that formed at 3 hours did 
not strongly co-localize with F95 staining (Fig. 2-6A-D, asterisks). GFAP filaments that were extended 
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Figure 2-5. Citrullination along Vimentin Filaments after Ocular Injury. 
 
Cryosections from uninjured and injured eyes were stained using antibodies against vimentin (red) and 
citrullinated proteins (F95; green). Tissue sections were examined under confocal microscope at 20X 
maginification from uninjured eyes (A-C), and 1 hour (D-F), 3 hours (G-I), 1 day (J-L) and 3 days (M-O) 
post injured eyes. Extensions of vimentin staining beyond nuclei of GCL are marked by arrow (I, O). 
Representative regions showing the overlap of vimentin and F95 antibodies are marked by asterisks (F, I, 
O). Interspersed regions of vimentin and F95 reactivity is outlined in brackets (F, I, O). Diffuse staining  of 
F95 is marked by arrowhead (O). GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear  
layer; OPL, outer plexiform layer; ONL, outer nuclear layer. (Scale bar = 100 µm ) 
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by 3 days showed strong co-localization with F95 immunoreactivity (Fig. 2-6E-H, asterisks). Importantly, 
extension of GFAP positive processes into vitreal space occurred as early as 3 hours after injury (Fig. 2 - 
6C, bracket). Co-staining of vimentin and citrullinated epitopes at 3 hours (Fig. 2-7 A-D, asterisks) 
appeared to be restricted to the layers of the inner retina (GCL, IPL), while there was a distinct and clear 
staining of vimentin at 3 days (Fig. 2-7 E-H) at the INL and near the border between the IPL and the INL. 
At this later time point F95 staining became more distinct, as glial processes stained with both vimentin 
and GFAP displayed an interspersed staining with citrullinated proteins (Fig. 2-6G, brackets; Fig. 2-7G, 
brackets), while vimentin and GFAP positive glial sprouts themselves extended through the retina (Fig. 2 - 
S3). 
Immunostaining of Müller glia does not always provide the possibility of visualizing filaments 
fully, due to the changing contours of the tissue. In order to more completely probe the nature of the IF 
relationship with F95 reactive species along the length of entire filaments through the contour of the retina, 
we compiled z stacks of confocal images into movies. Using tissue sections from 3 hour and 3-day post-
injury time points, samples were stained with either GFAP and F95 or vimentin and F95. When we 
examined GFAP immunoreactivity at 63X magnification 3 hours post injury (Sup. 2-M1), filaments 
extending into the INL were observed. When filaments were examined throughout the z-stack, both regions 
of “interspersed” filamentous structures and co-localized regions could be identified (Sup. 2-M1). Several 
GFAP negative, F95 positive filaments were also observed. When we examined GFAP and F95 
immunoreactivity at 3 days post injury (Sup. 2-M2), GFAP filaments were tracked from the GCL through 
the INL. At 3 days, fewer GFAP negative F95 positive filamentous structures were observed. Regions of 
co-localization were observed mainly in the IPL. When examined at 3 hours post injury, vimentin 
immunoreactivity appeared diminished in the outer retina (Sup. 2-M3). F95 positive, vimentin negative 
filamentous structures were not observed at 3 hours post injury. Filaments predominantly displayed both 
F95 and vimentin immunoreactivity, with several F95 positive regions interspersed near the boundary of 
the IPL and the INL. At 3 days post injury (Sup. 2-M4), vimentin positive filaments were observed 
extending from the ONL to the GCL. F95 immunoreactivity was also observed in the INL. Vimentin and 
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Figure 2-6. High magnification images of citrullinated GFAP filaments in the injured retina. 
 
Tissue sections of mouse eyes injured for either 3 hours or 3 days were immunostained for GFAP (A, E, 
red), citrullinated proteins (B, F, F95 antibody, green) and nuclei (C, G, merged images, DAPI-blue). 
Sections were analyzed on a Zeiss LSM 780 confocal microscope at 63X magnification to identify GFAP 
filaments co-localized with citrullinated species. Co-localized filaments in 3 hour (C, D, asterisk) and 3 day 
samples (G, H, asterisk) were visually identifiable in the inner plexiform layer (IPL). Orthogonal planes 
were analyzed (D, H) to identify points of co-localization (asterisks, arrowheads). Invasion of filaments 
into the vitreal space past the ganglion cell layer (GCL) was identified in 3 hour injured samples (C, 
bracket).  (Scale bar = 40 µm) 
52 
 
 
 
 
 
Figure 2-7. High magnification images of citrullinated vimentin filaments in retinas after ocular 
injury. 
Eyes injured for either 3 hours or 3 days were sectioned and immunostained for vimentin (A, E, red), anti- 
citrullinated proteins (B, F, F95 antibody, green) along with DAPI (C, G, merged images, blue). Vimentin 
filaments showed staining in the GCL and IPL 3 hours post-injury (A). F95 positive filaments showed 
staining at 3 hours post-injury in the GCL and IPL (B). Filaments in the retina displayed co-localization  of 
F95 and vimentin (C, asterisk; D, asterisk/arrowhead), as well as a distinct interspersed pattern with F95 
reactive regions capping filaments near the boundary of the IPL and INL (C, arrow). Three days post- injury, 
vimentin positive filaments showed staining in the IPL and both filamentous and non-filamentous vimentin 
immunoreactivity was present in the GCL (E). Diffuse staining, as well as filamentous staining of F95 
reactive proteins were present in the GCL and IPL 3 days post-injury (F). Vimentin and F95 displayed 
distinct co-localization (G, asterisk; H asterisk, arrowhead), as well as an interspersed pattern (G, bracket). 
Orthogonal views of xyz stacks (D, H) were obtained to identify points of co-localization  (D, H, asterisk, 
arrowhead). (Scale bar = 40 µm) 
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F95 immunoreactivity along the continuous filamentous structures was predominantly co-localized. An 
interspersed pattern was observed with vimentin and F95 immunoreactivity immediately adjacent to this 
pattern (Sup. 2-M4, Fig. 2-7G, bracket). These data indicate that citrullination in the Müller glia can 
associate with the IF cytoskeleton and appears to be dynamically altered as the filaments form post injury. 
 
 
Targeting Citrullination and the IFs in retinal gliosis reduces GFAP and Vimentin 
 
We next hypothesized that citrullination plays a role in the injury response of the retina and could impact 
gliosis. To test this hypothesis we employed the PAD inhibitor Cl-amidine and exploited a retinal posterior 
eye-cup organ culture model as a convenient biochemical assay. The retinal posterior eye-cup model was 
previously employed to test inhibitors of gliosis in vitro using enucleated eyes from mice that had been 
subjected to alkali injury to promote gliosis [13]. This biochemical assay provides the advantage of not 
only relatively short time period to test drugs by bath application but also avoids issues with variability in 
tissue permeability and unknown pharmacodynamics faced with in vivo drug delivery to the retina. Thus, 
using the intact posterior eye cups dissected from 7-day post injured eyes, pilot experiments were performed 
to optimize the assay to ascertain dose-related effects of Cl-amidine compared to vehicle, finding a 100 µM 
dose of Cl-amidine effective at decreasing a broad range of citrullinated species (Fig. 2- S4). We then 
investigated how perturbation of soluble IFs with a low dose of WFA used alone, or in combination with 
Cl-amidine, affected citrullination. Interestingly, we found that injured retinas showed, in addition to the 
anticipated 50 kDa GFAP, also high molecular weight GFAP species (>75 kDa) in the soluble (Fig 2-8A-
B) fraction, and displayed a pattern similar to that previously documented in human CNS disease [36]. 
Whereas Cl-amidine treatment alone reduced abundance of some of the high molecular weight (species > 
75kDa) GFAP species (Fig. 2-8A-B), combined treatment of Cl-amidine and WFA significantly reduced 
high molecular weight GFAP (>75 kDa) in the soluble fraction of proteins (Fig. 2- 8A-B). Cl-amidine also 
caused levels of low molecular weight (37-50 kDa) GFAP to be increased (Fig. 2- 8A), though not to 
statistical significance (Fig. 2-8C). Cl-amidine treatment did, however, significantly increase the native 50 
kDa GFAP species in the soluble fraction (Fig. 2-8A, asterisk). Combined 
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Figure 2-8. WFA and Cl-amidine have a compounding effect on soluble GFAP in the retina. 
 
Eyes were injured and left to recover for 7 days in vivo. On day 7, mouse eyes were enucleated and 
posterior eye-cups were placed into culture with no drug added (lane 1), or containing either Cl- amidine 
alone (lane 2), WFA alone (lane 3), or both drugs combined (lane 4). (A) Western blot analysis of GFAP 
in soluble fractions of untreated, Cl-amidine treated, WFA treated, or WFA/Cl-amidine treated eye-cups. 
The arrowhead points to a 55 kDa band. Densitometric quantification of high molecular weight GFAP (B, 
>75 kDa), low molecular weight GFAP (C, 37-50 kDa), or 50 kDa GFAP (D, asterisk). (E) Western blot 
analysis of F95 in soluble fraction from untreated, Cl-amidine treated, WFA treated, or WFA/Cl-amidine 
treated eye-cups. Data are mean +/- SD, *= p<0.05 by t-test. 
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treatment with WFA and Cl-amidine increased levels of low molecular weight (37-50kDa) GFAP (Fig. 2- 
8A, 2-8C), though not significantly when normalized to β-Actin (Fig. 2-8C). A 55 kDa band was visibly 
decreased by both WFA and Cl-amidine treatment alone, and extracts from the combined treatment 
displayed no observable 55 kDa species (Figure 2-8A, arrowhead). Analysis of F95 antibody reactivity 
showed treatment with both Cl-amidine and WFA clearly diminished the levels of most of the high 
molecular weight citrullinated proteins in the soluble fraction (Fig. 2-8E). Analysis of the insoluble fraction 
of proteins showed no statistical difference in GFAP levels (Fig. 2-9A-D), but changes in the migration of 
these species were observed (Fig. 2-9A). Cl-amidine treatment caused a trend towards increasing 
abundance of the 50 kDa GFAP species as well as low molecular weight GFAP (37-50 kDa) in the insoluble 
fraction, but these were not significant when normalized to GAPDH (Fig. 2-9C, D). This effect was not 
seen with WFA treatment alone. Taken together, our data demonstrate that low dose WFA when used in 
conmbination with Cl-amidine enhanced the targeting of protein citrullination and restored levels of 50 
kDa soluble GFAP. 
In comparison, high molecular weight vimentin was not readily detected in the soluble extracts 
(Fig. 2-10A). Interestingly, treatment with Cl-amidine provided alone, or WFA alone, increased abundance 
of the 55 kDa and lower species (Fig 2-10A, arrowhead, B). Combined drug treatments significantly 
increased the native 55 kDa vimentin species (Fig. 2-10A, C). On the other hand, the insoluble extracts did 
not reveal any significant changes in vimentin levels with either drug treatments (Fig. 2-10D-F). Taken 
together, these biochemical experiments reveal that significant changes in the composition of the soluble 
pool of GFAP were affected by injury that lead to increased citrullination of this IF protein, with alterations 
in soluble vimentin being a minor feature of this complex reactive glial response. 
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Figure 2-9. WFA and Cl-amidine have no effect on insoluble GFAP in the retina. 
 
Eyes were injured and left to recover for 7 days in vivo. On day 7, mouse eyes were enucleated and posterior 
eye-cups were placed into culture with no drug added (lane 1), or containing either Cl-amidine alone (lane 
2), WFA alone (lane 3), or both drugs combined (lane 4). (A) Western blot analysis of GFAP in insoluble 
fraction of untreated, Cl-amidine treated, WFA treated, or WFA/Cl-amidine treated eye-cups. 
Densitometric quantification of high molecular weight (B, >75 kDa), low molecular weight (C, 37-50 
kDa), and 50 kDa species (D, arrowhead). Data are mean +/- SD, *= p<0.05 by t-test. 
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Figure 2-10. WFA and Cl-amidine alter the distribution of vimentin in the retina 
 
Eyes were injured and left to recover for 7 days in vivo. On day 7, mouse eyes were enucleated and posterior 
eye-cups (neural retina, pigment epithelium, choroid) were placed into culture containing specified 
concentration of either Cl-amidine (lane 2), WFA (lane 3), both (lane 4) or no drug added (lane 1). (A) 
Western blot analysis of vimentin in soluble fractions of untreated, Cl-amidine treated, WFA treated, or 
WFA/Cl-amidine treated eye-cups. Densitometric quantification of low molecular weight vimentin (B, 37-
55 kDa), or 55 kDa vimentin (C, arrowhead). (D) Western blot analysis of vimentin in insoluble fraction 
of untreated, Cl-amidine treated, WFA treated, or WFA/Cl-amidine treated eye-cups. Densitometric 
quantification of low molecular weight (E, 37-55 kDa), and 55 kDa species (F, arrowhead). Data are mean 
+/- SD, *= p<0.05 by t-test. 
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2.5 Discussion 
 
We report for the first time that citrullination is an induced response to injury within Müller glial cells of 
the mouse retina. This PTM occurs on a global level in different cell layers of the retina, but a major 
citrullinated target, GFAP, and to a lesser extent vimentin, are two important proteins of the Müller glial 
response responding to injury [171, 172, 8, 55, 178, 24]. The discovery that the soluble form of GFAP 
becomes citrullinated after injury provided us the opportunity to demonstrate that perturbation of the IFs 
directly by WFA [13] when combined with the pan-PAD inhibitor Cl-amidine can interfere with 
citrullination. Our data is intriguing as there has been growing interest in the roles of soluble IFs, for 
instance, as chaperones [76] and in nuclear transport of kinases in injured neurons and corneal fibrosis [76, 
77], as well as in lamellipodia formation [77, 73]. Several prior studies have focused on the Müller glial 
responses in different injury contexts [176, 186, 17, 13, 46, 191], but the immediate responses of IF proteins 
where soluble forms are regulated have not been studied. Also of note is the fact that although this study 
focuses on glial responses, and did not examine neuronal responses, retinal ganglion cells can become 
apoptotic after alkali injuries [192]. Our findings illuminate citrullination of IFs as an important early event 
in the injury response of the retina. 
 
 
The citrullinated GFAP isoforms that result from this severe alkali injury showed a wide 
distribution of both basic and acidic species that contain the antigenic R267 or R413 citrullination sites. 
These data do not rule out that other arginines in GFAP could be citrullinated, as their mobilities in the 2D 
western blot analysis were clustered together. The presence of acidic citrullinated GFAP species, however, 
indicate that phosphorylation may also be contributing to the solubility of these GFAP  filaments, as 
increased phosphorylation is known to depolymerize cytoskeletal forms of IF proteins [180, 193]. 
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Interestingly, we found that the retinal explant culturing process enhanced the extent of 
citrullination causing hypercitrullination, making this explant biochemical assay not only reliable, but also 
suitable for drug testing under controlled conditions. The hypercitrullination pattern observed in cultured 
retinal explants appeared similar to that reported for human astrocytes cultured under hypoxia where the 
early detection of PAD enzyme and that of a ~65 kDa GFAP citrullinated isoform was also reported [156]. 
The robust hypercitrullination being observed largely in the soluble fraction, in stark contrast to  the minor 
changes in citrullination in the insoluble fraction, indicated that the majority of citrullinated proteins in 
this system represent proteins that were solubilized at low salt conditions. These data, in conjunction with 
the diffuse citrullinated GFAP spots seen by 2D western blots and the interrupted staining pattern of F95 
in GFAP-containing filaments, suggested that dynamic exchange of citrullinated and phosphorylated 
soluble GFAP with filamentous structures may be occurring during gliosis. It is possible that citrullination 
of vimentin may also alter antigenic reactivity, as it does with GFAP [193]. It will be important in the future 
to examine citrullination patterns of both GFAP and vimentin in less severe retinal injuries that recover 
structural integrity to ascertain how the phenotype-biomarker relationship in retinas changes in models of 
reversible gliosis that promote healing over fibrosis. 
 
 
Since WFA and Cl-amidine both have established targets with pathological roles that can be inhibited at 
non-toxic drug doses [116, 13, 46, 151, 153, 67, 162], our interest in knowing whether  these drug targets 
interacted to affect global citrullination revealed an interesting result. Binding of WFA to soluble IFs [13], 
which likely causes increased IF phosphorylation [153, 77], was found to increase the effectiveness of PAD 
inhibition for inhibiting global citrullination. One explanation for the synergistic drug effect is that WFA-
bound soluble GFAP may complex with active PADs, and thereby, sensitize PADs to Cl- amidine. Soluble 
phosphorylated vimentin bound by WFA has been shown to complex with phosphorylated ERK1/2 and 
filamin A in myofibroblasts and co-exist in multimeric protein complexes that blocked nuclear 
translocation of pERK1/2 by WFA treatment [77]. Similarly, complexes between 
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soluble GFAP and PADs might be induced by WFA activity that could effectively alter PAD intracellular 
localization or its activity through mechanisms as yet unknown. 
 
 
The presence of IFs that display a colocalization with citrullinated epitopes at the early stages after 
injury and temporal changes observed along both established and developing filaments, implicate this PTM 
as a likely dynamic regulator of cytoskeletal alterations in Müller glia. The confocal microscopic orthogonal 
views highlight this importance by noting that not only were citrullinated  epitopes directly co-localized 
with IFs from the earliest stages, but these modifications also occurred interspersed along the length of 
filaments. Immunohistochemical analysis of injured retinas also showed a protrusion into the vitreal space 
that is reminiscent of the “glial sprouts” (Fig. 2-S3), which show some similarity to idiopathic human 
retinas from AMD patients [40]. These extensions into the vitreal space indicate a breakdown in inner 
limiting membrane (ILM) integrity, which is made largely from Müller glial end feet. To this end, it will 
be important in the future to examine how such changes to the IFs impacts the architecture of the Müller  
cell. 
 
 
The initial activation in injury indicates that the Müller cells, with their position near the vitreous space and 
presence of stretch receptors [194], are the major glial sensors in the retina and organizers of retinal injury 
response. Our findings parallel those found using the laser injury model that showed  early reactivity of 
Müller glia that precede choroidal neovascularization, suggesting gliosis sensitizes the entire retina to 
retinal pigment epithelial injury [195, 196]. Recent research has found that both citrullination and PAD 
levels were increased after exposure to increased ocular pressure (IOP) [38, 39, 183, 197]. The mouse alkali 
injury models clinical alkali injuries associated with glaucomatous pathology and increased IOP [61]. 
Müller glial cells responding to such increased IOP may be responsible for the increase in citrullination we 
observed after injury and in glaucoma. While the in vivo injury maintains pressure throughout the vitreous, 
the explant system devoid of this increased IOP could trigger the response of 
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Müller glia, possibly accounting for the differences seen between the in vivo injury and the explant culture 
system. 
Gliosis has remained an untreatable condition, despite numerous attempts to unravel the intricate 
responses involved in the mammalian system. Here, we have identified that the PTM of citrullination is an 
important mechanism in reactive gliosis that could provide a druggable target for retinal disorders as it has 
in other clinical conditions [198]. 
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Fig. 2-S1. Two Dimensional IEF analysis of GFAP from injured retinas. 
 
Eyes from 7 day injured mouse retinas were collected and retino-choroidal tissues from the posterior eye- 
cups were extracted into the soluble lysate. This soluble fraction was directly separated by 2-dimensional 
gel electrophoresis and protein blot was probed with the rabbit anti-GFAP antibody that recognizes native 
unmodified species. 
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Fig. 2-S2. Overlaid images of GFAP and citrullinated GFAP. 
 
Mouse eyes were injured and left to recover for 7 days in vivo. On day 7, retino-choroidal tissues from  the 
posterior eye-cups were extracted into soluble fractions. The soluble fractions were then either (A) directly 
separated by 2-dimensional gel electrophoresis or (B) immunoprecipitated for F95  reactive species and 
then separated by 2-dimensional gel electrophoresis. The protein blots from these analysis were then probed 
for (A) total GFAP or (B) citrullinated GFAP (CGTF-1221 antibody). The digital images were then overlaid 
(C) to compare different GFAP species (red) with those that contained citrullinated species  (green). 
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Figure 2-S3. Glial Sprouts as a Result of Alkali Injury 
 
Mouse eyes were either left uninjured or injured and left to recover for 3 days. Eyes were then examined 
by immunohistochemistry at uninjured or 3 days for GFAP (A-B) or vimentin (C-D) and treated with DAPI 
to stain nuclei. (Scale bar =70 µm) 
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Fig. 2-S4. Response of citrullinated proteins to Cl-amidine dosage in posterior eye-cup explant 
culture. 
Mouse eyes were injured and left to recover for 7 days in vivo. On day 7, eyes were enucleated and intact 
posterior eye-cups were placed into culture with vehicle DMSO (lane 1) or different concentrations of Cl- 
amidine (lanes 2-4) for 3 days. Retino-choroidal tissues from the posterior eye-cups were extracted and 
soluble fractions analyzed by western blotting for citrullinated proteins (F95 antibody), and subsequently, 
for β-tubulin on the same membrane for loading control. 
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Fig. 2-M1: Co-localization of Citrullination on GFAP Filaments at 3 hours 
 
Plane-by-Plane Confocal Imaging of 3 Hour Injured eyes Immunostained for F95 (green), GFAP (red), 
DAPI (blue). Confocal z-stacks were obtained on a Zeiss 780 Confocal microscope at 63X. Individual 
planes were then increased in brightness to the same level in Lightroom. Images were re-assembled as   a 
.mov at 0.5 seconds per focal plane. Images encompass planes containing GFAP filaments to highlight co-
localization with citrullinated species over the length of individual filaments. 
Fig. 2-M2: Co-localization of Citrullination on GFAP Filaments at 3 days 
 
Plane-by-Plane Confocal Imaging of 3 Day Injured eyes Immunostained for F95 (green), GFAP (red), 
DAPI (blue). Confocal z-stacks were obtained on a Zeiss 780 Confocal microscope at 63X. Individual 
planes were then increased in brightness to the same level in Lightroom. Images were re-assembled as   a 
.mov at 0.5 seconds per focal plane. Images encompass planes containing GFAP filaments to highlight co-
localization with citrullinated species over the length of filaments. 
Fig. 2-M3: Co-localization of Citrullination on Vimentin Filaments at 3 hours 
 
Plane-by-Plane Confocal Imaging of 3 Hour Injured eyes Immunostained for F95 (green), vimentin (red), 
DAPI (blue). Confocal z-stacks were obtained on a Zeiss 780 Confocal microscope at 63X. Individual 
planes were then increased in brightness to the same level in Lightroom. Images were re-assembled as   a 
.mov at 0.5 seconds per focal plane. Images encompass planes containing vimentin filaments to highlight 
co-localization with citrullinated species over the length of individual filaments. 
Fig. 2-M4: Co-localization of Citrullination on Vimentin Filaments at 3 days 
 
Plane-by-Plane Confocal Imaging of 3 Day Injured eyes Immunostained for F95 (green), vimentin (red), 
DAPI (blue). Confocal z-stacks were obtained on a Zeiss 780 Confocal microscope at 63X. Individual 
planes were then increased in brightness to the same level in Lightroom. Images were re-assembled as   a 
.mov at 0.5 seconds per focal plane. Images encompass planes containing vimentin filaments to highlight 
co-localization with citrullinated species over the length of individual filaments. 
67 
 
Chapter 3 
 
Expression and Contribution of Peptidylarginine Deiminase (PAD) 4 Enzyme to Retinal 
Gliosis 
John W. Wizeman and Royce Mohan 
 
Author Contributions: 
 
John Wizeman: Conception and design of experiments, collection, analysis and interpretation of 
results, manuscript writing 
Royce Mohan: Conception and design of experiments, interpretation of results, financial support, 
manuscript writing 
 
 
This chapter prepared to be submitted in a peer-reviewed journal. 
 
 
 
3.1 Introduction 
 
Retinal gliosis is a reactive process that underlies most retinal pathologies [8, 22]. Astrogliosis in 
all areas of the central nervous system (CNS) has many similar characteristics [199, 200]. In the retina it  
is undertaken by Müller glial cells and the ganglion cell layer astrocytes [22, 40]. These cells provide 
trophic and structural support to the neuronal cells of the retina [8, 22]. The reactivity seen in both injury 
[13, 46, 17, 192] and disease [201] is often characterized by the increased expression of the type III 
intermediate filament (IF) proteins vimentin and glial fibrillary acidic protein (GFAP) [13, 46]. While  
GFAP and vimentin are the cytoskeletal proteins in the uninjured astrocyte and Müller cell, respectively, 
these proteins are upregulated in pathological conditions, to both the benefit and the detriment of the retina 
[22, 202]. A better understanding of the IFs, from both a physiological and pharmacological [14, 13] 
standpoint remains an important goal to be achieved. 
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One of the ways in which the IFs are controlled in vivo is by post-translation modification [77]. 
Among these is the relatively understudied modification known as citrullination [33]. Citrullination, or 
deimination, is a calcium dependent post-translational modification to arginine that removes a positive 
charge [34]. This process is carried out by the peptidylarginine deiminase (PADs, EC 3.5.3.15) family of 
enzymes. In mammals there are five PAD enzymes, often found to have differing tissue expression [34]. 
Interestingly, PAD4 is abundant at the synovial joint in rheumatoid arthritis [37], where there is a coincident 
increase of citrullinated vimentin in human patients [221]. This citrullinated vimentin is a biomarker of 
disease in RA [37] 
In the mammalian retina, citrullination levels are increased in patients with Age-Related Macular 
Degeneration (AMD) compared to controls [38]. In cultured astrocytes, PAD enzyme and citrullination 
levels are increased when subjected to increases in mechanical pressure [183]. Increased levels of 
citrullination and PADs have been identified in a number of different CNS disorders, including Alzheimers 
Disease [19, 134], Glaucoma [39], Parkinsons Disease [134], Scrapie [144], Creutzfeldt- Jakob Disease 
[145], and Multiple Sclerosis (MS) [35]. In MS, the PAD4 enzyme is overexpressed and can translocate to 
the nucleus to citrullinate histone H3 [203]. The direct contribution of PAD4 and the effect of deimination 
on different targets remain unknown in many of these diseases. 
Previously, we have shown that GFAP and vimentin levels are increased [13] and filaments become 
deiminated after injury. This change happens quickly after injury (1 hour), and can be targeted by a 
synthetic PAD inhibitor in an ex vivo retinal explant system that induces hypercitrullination. Here, we set 
out to determine the expression and location of the PAD4 enzyme, associated with CNS disorders, in the 
injured retina. We found that several PAD genes are transcribed in the uninjured and injured retina, and 
that the different isozymes have different cellular sources, although both PAD2 and PAD4 are expressed 
in glial cells. Further, these enzymes can be targeted by intravitreal injection in the retina after injury. 
Surprisingly, by targeting PAD4 with streptonigrin [168], a potent PAD4 specific inhibitor, we were able 
to show a decrease in detectable levels of GFAP. This new information indicates that the  PAD 
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enzymes are present in the retina, meaning that they could react quickly to changes after injury or slowly 
during disease, and that this modification may play an important role in the initiation of gliosis.  
 
 
3.2 Materials and Methods 
Mice 
All animal experiments were conducted in accordance with procedures approved by IACUC committee of 
the University of Connecticut Health Center. Mice were housed in specific pathogen free cages in 
designated laboratory animal housing facilities. 
 
 
Alkali Injury 
 
Corneal alkali injuries were performed in 129S6/SvEVTac (Taconic, Hudson, NY) mice as previously 
described [13, 46] between 2 and 3 months with a minor modification. Mice were given an intraperitoneal 
(i.p.) injection of Ketamine/Xylazine, and corneas were anesthetized with proparacaine eye drops. A 1 µl 
drop of 1N sodium hydroxide was then applied directly to the central cornea for 45 seconds. Following 
injury, the eye was immediately flushed extensively with sterile phosphate buffered saline (PBS) solution. 
The corneal epithelium was gently removed using a Tooke knife, and eyes were then treated topically with 
atropine, followed by tobramycin and erythromycin. For time course studies, injured mice were treated 
daily with topical applications of tobramycin and erythromycin for 3 days post-injury and humanely 
sacrificed by CO2 inhalation at different times. 
 
 
RNA extraction, RT-PCR and qPCR 
 
RNA was extracted from the indicated tissues using a Qiagen RNeasy Mini Kit (Cat #74104, Qiagen)  
according to manufacturers instructions. RNA was treated with DNAse (Ambion AM1907) to remove 
contaminating genomic DNA. RNA was then reverse transcribed into corresponding cDNA using 
SuperScript III Reverse Transcriptase and diluted to 75 ng/ul. Tissue was screened for each of the  
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following primer pairs: GAPDH (For 5’ – ATG ACA TCA AGA AGG TGG TG; Rev 5’ CAT ACC  AGG 
AAA TGA GCT TG); PAD2 (For 5’ – GTT ATG TTC AAG GGC CTG GGA GGC ATG; Rev  5’ 
– TAG CAC GAT CAT GTT CAC CAT GTT AGG); PAD3 (For 5’ – TTC TCC GAG ACC CCC ATC 
TT; Rev 5’ – TTA TTC CTC ACC CGG CAC AC); PAD4 (For 5’ – CGA TTG GCT CTT TGT GGG TC; 
Rev 5’ – CCG AAA ACC CTG CTT GTC C; or For 5’ – TCT TTG TGG GTC ACG TGG ATG 
AGT; Rev 5’ AGC TCC TGG AAC AGC TGA TAG CAA) and under the following cycling conditions: 
GAPDH – RT-PCR 1: 94C for 3 minutes; 2: 94C for 30s; 3: 45C for 30s; 4: 72C for 1 minute; repeat 2-4 
for 35X; 72C for 5 minutes; qPCR – 1: 95C for 1 minute, 2: 95C for 15s, 3: 60C for 30s, repeat 2-3 for 
40X; PAD2 – RT-PCR 1: 94C for 3 minutes, 2: 94C for 40s, 3: 57C for 30s, 4: 72C for 40s, repeat 2-4 for 
35X, 5: 72C for 7 minutes; qPCR – 1: 95C for 3 minutes, 2: 95C for 30s, 3: 55C for 30s, repeat 2-3 for 
39X; PAD3 – RT-PCR 1: 94C for 3 minutes, 2: 94C for 1 minute, 3: 58 C for 1 minute, 4: 72C for 3 
minutes, repeat 2-4 for 40X, 5: 72C for 10 minutes; PAD4 – RT-PCR 1:94C for 3 minutes, 2: 94C for 30s, 
3: 52C for 30s, 4: 72C for 45s, repeat 2-4 for 34X, 5:72C for 5 minutes; qPCR – 1: 95C for 3 minutes, 2: 
95C for 15s, 3: 51.5C for 45s, repeat 2-3 for 40X. Triplicates were analyzed by qPCR for GAPDH, PAD2 
and PAD4 on a Bio-Rad CFX96 Touch real time PCR detection system. Fold change (normalized to 
GAPDH levels) was compared to uninjured and is expressed as fold change +/- standard deviation. 
Statistical differences were identified by two-tailed t-test. 
 
 
Antibodies 
 
The antibodies used were GFAP (IHC: EMD Millipore AB5541 1:500; WB: AB7260 1:4,000), PAD2 
(Abcam ab50257 1:50), PAD4 (IHC: Abcam ab50247 1:100; WB: Bioloegend #684202 1:1,000), β-III 
Tubulin (Abcam ab18207 1:100), F95 antibody for citrullinated proteins (EMD Millipore MABN328 1:50), 
GAPDH (Santa Cruz sc-25778 1:1,000), goat anti-mouse IgM 488 (Alexa 1:500), goat anti-rabbit 488 
(Alexa 1:500), goat anti-chicken 594 (Alexa 1:500), goat anti-rabbit 594 (Alexa 1:500), goat anti- rabbit 
HRP (Santa Cruz 1:1,000), goat anti-mouse IgM HRP (Jackson Immunoresearch 1:5,000). 
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Protein Extraction and Western Blotting 
 
Three mouse eye-cups were placed in ice-cold soluble buffer (20 mM Tris buffer, 200 mM NaCl, 1% NP- 
 
40) supplemented with a proteinase inhibitor cocktail (Roche, Indianapolis, IN) and tissue was minced into 
pieces on ice. Samples were left on ice for 45 minutes and then spun at 14,000 RPM for 5 minutes at 4 
o
C. 
The supernatant was removed and labeled as the “soluble” fraction (containing soluble forms of IF 
proteins). Lysates were then passed repeatedly through a 26-gauge needle 10 times to shear DNA. After, 
Bicinchoninic Acid Assay (Pierce, Waltham, MA) was used for quantification of protein. Protein samples 
were boiled 95-100 
o
C for 5 to 10 minutes in Laemmli buffer and then loaded on 4-20% Tris-HCl SDS- 
polyacrylamide gels (Bio-Rad). Proteins were transferred onto a 0.2 µm PVDF membrane (Bio-Rad, 
Hercules, CA). Membranes were blocked in 5% milk in 1X Tris Buffered Saline + Tween (TBST) for 1  
hour at room temperature, then incubated with primary antibody for 1 hour at room temperature or 
overnight at 4
o 
C. Membranes were washed 3 times for 15 minutes, then incubated with secondary antibody 
for 45-60 minutes at room temperature. Membranes were washed 4 times for 15 minutes and 
developed with Enhanced Chemiluminescence (ECL; Bio-Rad) solution. To normalize for protein loading, 
membranes were stripped in 10X Tris-Glycine-SDS buffer for 30 minutes at RT, then probed as above with 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). All figures are shown with corresponding GAPDH 
control beneath. Western blots were then quantified using ImageJ to generate densitometric graphs. 
Experiments were repeated three times, and are presented as mean +/- standard deviation (SD). Significance 
was determined by t-test (p ≤ 0.05). 
 
 
Intravitreal injections 
 
1ul of 125nM streptonigrin (Sigma) was injected intravitreally, assuming a final volume of ~5ul by 
Hamilton Syringe, to achieve ~25nM final concentration. Mice were injured in vivo and humanely 
sacrificed by CO2 inhalataion. After sacrifice, eyes were enucleated and kept in 1X Phosphate   Buffered 
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Saline (PBS) +Antibiotic/Antimycotic (GE Life Sciences), at RT until injection. First, an initial puncture 
of the outer layers of the globe was made using a Becton Dickinson 30G x ½ in needle, keeping intact the 
globe structure (BD #305106). Next, we injected 1 ul of streptonigrin dissolved in DMSO/PBS directly 
into the vitreal space. After injection, eyes were incubated for 5 hours at 37C and 5% CO2. After 5 hours, 
posterior eye-cups were separated from the anterior eye and subjected to protein extraction as described. 
 
 
3.3 Results 
 
PAD2 and PAD4 mRNA transcripts are detectable in the retina 
 
We employed an ocular injury model that induces retinal gliosis [13, 46] to identify changes in the 
expression of PAD enzymes within the central nervous system. Previously, we have shown that there are 
increases in citrullinated proteins as early as 1 hour after injury (Chapter 2). These citrullinated epitopes 
are found along GFAP and vimentin filaments within Müller glial cells of the retina, and GFAP specifically 
has been shown to be citrullinated. It has been previously reported that PAD2 is present in the retina and 
optic nerve of patients with glaucoma [197] and AMD [38]. Additionally, PAD3 is expressed  in human 
neural stem cells [123], and PAD4 is found in the brain of Alzheimer's [143] and Multiple Sclerosis [203] 
patients. We set out initially to determine the expression of the known neural PAD enzymes in the uninjured 
and injured retina. PAD2 transcript was found in the uninjured and injured retina (Fig 3-1A), although 
present at modestly higher levels in the uninjured retina than 7 days after injury (Fig. 3-1A, B). PAD3 
transcript was absent in the retina at all stages (Fig. 3-1A). PAD4 transcript was found in both the injured 
and uninjured retina (Fig. 3-1A,C) though increased in the retina greater than 4 fold early after injury and 
greater than 24 fold by 7 days (Fig. 3-1D). Due to the reported expression patterns we did not screen for 
PAD1 [106] or PAD6 [133] transcripts in the injured or uninjured retina. 
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Figure 3-1. PAD2 and PAD4 transcripts are expressed in the retina 
 
PCR analysis of PADs 2-4 in the uninjured posterior eye-cup (unj) and eye-cups at 1 hour (1h) and 7 days 
(7d) post injury. (A) RT-PCR products from different timepoints run on a 1.2% agarose gel. Positive 
controls contained cDNA from brain, spleen, skin and hair. H2O was run as negative control. (B) 
Quantitation of fold change (normalized to GAPDH levels) identified by qPCR of PAD2 transcripts at 
different timepoints compared to uninjured qPCR. (C) Quantitation of fold change (normalized to GAPDH 
levels) identified by qPCR of PAD4 transcripts at different timepoints compared to uninjured qPCR results 
(* = p ≤ 0.05, t-test). 
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PAD4 protein is increased in the injured retina 
 
The identification of increased levels of PAD4 transcript suggested that the PAD4 protein may be 
responsible for deimination in the posterior eye-cup. We therefore set out to determine whether PAD4 
protein levels were also altered by injury. When we examined levels of PAD4 in the uninjured and injured 
retina, we observed that a ~65-67 kDa species was significantly increased in the injured retina over 
uninjured controls (Fig. 3-2A,B, Unj =1.91±.0.38; 7d=3.59±0.42). PAD4 immunoreactivity was also 
observed in the uninjured posterior-eye cup. Interestingly, we also observed a PAD4 immunoreactive 
cleavage product at 50 kDa in the injured eye (Fig. 3-2A). 
 
 
PAD2 is expressed in Astrocytes in the Uninjured Retina 
 
Having identified the PAD enzymes present in the injured and uninjured retina, we next wanted to localize 
PAD expression in the retina after injury. We have previously identified that citrullinated proteins are 
expressed along GFAP and vimentin filaments. This indicated that the location of modified species in the 
retina was likely in Müller glial cells or astrocytes. To test this hypothesis, we examined expression of 
PAD2 in uninjured and injured eyes along with GFAP expression. In the uninjured eye, PAD2 expression 
can be seen in the inner layers of the retina (Fig 3-3A, C), including GFAP positive cells in the ganglion 
cell layer and inner plexiform layer. 7 days after injury, we observed minimal PAD2 expression (Fig. 3- 
3D-F). GFAP increased expression throughout the layers of the inner retina after injury, as previously 
observed (Chapter 2). Disorganization seen in the ganglion cell layer mimics previous findings (Chapter 
2). 
 
 
PAD4 expression in the Uninjured and Injured Retina 
 
We next examined PAD4 expression in the same timeframe of injury. Again, GFAP expression was 
restricted to the ganglion cell layer astrocytes (Fig. 3-4A) in the uninjured eye. Surprisingly, in the uninjured 
eye, there was no distinct PAD4 protein expression pattern (Fig. 3-4B) identifiable by 
immunohistochemistry, despite the presence of an immunoreactive species by western blot. 7 days after  
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Figure 3-2. PAD4 Protein Expression is increased in the Injured Retina 
 
Western blot analysis of PAD4 protein in posterior eye-cups from uninjured mice (Unj, A lane 1) and eye-
cups from mice 7 days post injury (7d, A lane 2). Species immunoreactive against PAD4 antibody were 
identified in uninjured and injured eye-cups at ~65-70 kDa. Immunoreactivity against a ~50 kDa species is 
identifiable in the injured eye (lane 2). (B) Densitometric quantitation of immunoreactive bands with 
ImageJ ( * = p < 0.05, t-test). 
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Figure 3-3. PAD2 localization in the Uninjured and Injured Retina 
 
Cryosections from uninjured and injured eyes were stained using antibodies against GFAP (red) and PAD2 
(green). Tissue sections were examined under fluorescent microscope at 20X maginification from uninjured 
eyes (A-C), and 7 day (D-F) post injury eyes. (A) GFAP and (B) PAD2 expression was restricted to the 
Ganglion Cell Layer astrocytes (C) in the uninjured retina. Scale bar = 100 µm 
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Figure 3-4. Localization of PAD4 protein in the Uninjured and Injured Retina 
 
Cryosections from uninjured and injured eyes were stained using antibodies against GFAP (red) and PAD4 
(green). Tissue sections were examined under fluorescent microscope at 20X magnification from uninjured 
eyes (A-C), and 7 day (D-F) post injury eyes. (E, bracket) Filamentous PAD4 expression in the inner retina. 
GFAP filaments without PAD4 immunoreactivity (F, arrowheads). Protrusion of PAD4 positive cell into 
vitreal space (E, F, asterisk). Scale bar = 100 µm 
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injury, PAD4 expression was observed through the layers of the inner retina (Fig. 3-4F). This PAD4 
expression aligns with GFAP expression in Müller glial cells after injury. Interestingly, the expression of 
PAD4 did not coincide at a 1:1 ratio with GFAP filaments (Fig. 3-4E, F, arrowheads). PAD4 
immunoreactivity exhibited a filament like expression pattern (Fig 3-4E bracket), with PAD4 positive 
processes extending toward the vitreous (Fig. 3-4E, asterisk). 
 
 
Intravitreal Inhibition of PAD4 prevents GFAP expression 
 
Identifying PAD4 as a potential source of citrullination in Müller glial cells allowed us to more  thoroughly 
investigate its role in retinal healing. Streptonigrin [168, 169] is a potent and irreversible PAD inhibitor 
selective for PAD4. We modified a previous explant system [Chapter 2, 17] to allow for short- term 
assessment of reactivity after injury. We tested the effect of streptonigrin compared to a vehicle after 
intravitreal injection and 5 hour incubation. We found that streptonigrin reliably inhibited the citrullination 
response after injury, as observed by levels of the F95 antibody by western blotting (Fig. 3- 5A). 
Interestingly, streptonigrin was potent at reducing GFAP expression at a 25nM intravitreal dose (Fig. 3-5B, 
C; Veh=2.78±0.57; 25nM=1.56±0.12 p<0.05). 
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Figure 3-5. Intravitreal Injection of Streptonigrin downregulates GFAP expression in Injury 
Western blot analysis of citrullinated proteins (A), and GFAP (B, C) with and without intravitreal 
injection of streptonigrin. Mice were injured and sacrificed 10 minutes after injury. Eyes were enucleated 
and kept in PBS +A/A for 5 hours. Eyes were injected with either DMSO (veh) or with streptonigrin 
(25nM). After 5 hours, posterior eye-cups were dissected and soluble lysate extracted. Lysate was run on 
SDS-PAGE gel and examined for immunoreactivity to F95 antibody (A, citrullinated proteins) or GFAP 
(B). Quantitation of GFAP bands by ImageJ (C) after streptonigrin treatment (*= p<.05, t -test) 
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3.4 Discussion 
 
The control of retinal gliosis, specifically as it relates to the intermediate filaments, remains a goal 
within ocular research. Herein we have analyzed the levels of PAD4 transcript, PAD4 protein expression, 
and location of PAD4 after injury in the mouse retina. We have also identified citrullination  as an important 
factor regulating the GFAP protein expression throughout the retina. As GFAP is a reliable marker for 
retinal stress [8], specifically in Müller glia, we were able to use the alkali injury model to show that 
inhibiting PAD4 was able to alter the gliosis process by leading to a decrease in detectable levels of GFAP. 
This finding indicates that citrullination in the retina is mediated by two specific PAD enzymes, and that 
they play an important role in the initiation of gliosis. 
PAD4 is a known deimination target of itself [204]. Deimination of PAD4 decreases enzymatic 
activity, and can alter antigenic reactivity, as it does with GFAP. The identification of PAD4 in the 
uninjured retina, as well as the identification by immunoreactivity on western blot, suggests that the protein 
is expressed at some level within the uninjured posterior eye-cup. As this self-regulation of PAD4 may 
alter antigenic availability, the use of multiple PAD4 antibodies to fully examine PAD4 in the retina was 
required. The lack of immunogenic availability in the uninjured eye suggests that the pool of PAD4 protein 
in this condition may be a high turnover species. 
The finding that the PADs are present in the uninjured retina suggests that they are expressed as a 
way to respond immediately to a change in calcium [205, 206], which has been experimentally shown to 
increase in Müller glial cells after cell stretching [207]. PAD2, present in the uninjured retina, is known to 
citrullinate vimentin, another type III IF [113]. PADs 1-4 are many orders of magnitude more enzymatically 
active in the presence of calcium, creating an ideal system to respond to changes induced by increased 
mechanosensitivity from Müller glia after increases in intraocular pressure [194, 205], or as a mechanism 
to respond to changes from excess calcium release from dying neurons. The propagation of calcium waves 
between Müller glia and astrocytes also provides a mechanism to synchronize the retinal response across 
the entire retina [208, 209, 210]. 
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The development of more specific PAD inhibitors [211] has been beneficial not only in targeting 
the different PAD isozymes, but also in the identification of the targets and effects of specific PADs.  Here, 
the use of streptonigrin as a PAD4-specific inhibitor [169] allowed us to identify this as the isozyme 
responsible for the initiation of gliosis. The effects of citrullination on the intermediate filaments are still 
widely unknown. We have previously identified citrullinated species along GFAP and vimentin filaments 
as early as 1 hour after injury, as well as the presence of two different citrullinated GFAP isoforms. The 
presence of these isoforms in the soluble fraction indicates that they are harnessed by Müller cells for a 
non-cytoskeletal function, such as chaperones and for transport [76, 77] seen in other systems. The finding 
that inhibiting PAD4 causes a downregulation of GFAP levels, indicative of overall gliotic response, 
suggests it has an effect on Müller glia at the transcriptional level. Considering that PAD4 contains a nuclear 
localization sequence and can be found in the nucleus [212], one possible mechanism involves the 
activation of PADs in the Müller endfeet and astrocytes of the ganglion cell layer by the increase in calcium, 
which leads to their transport toward the Müller nuclei along GFAP and vimentin filaments to trigger a 
cell-wide transcriptional response. This is supported when realizing that the deimination that occurs quickly 
after injury (1 hour) and precedes a number of other factors, including immune reactivity, which are 
increased [192] later in the alkali injury model, or that accumulate at a number of different times in other 
injury and disease models [201, 17]. 
The control of GFAP and vimentin as a means of controlling gliosis in the retina is a goal that 
remains incomplete. Here, we have established a method by which the control of IFs by PTMs and their 
expression can be controlled within the retina. This opens the possibility of examining the use of specific 
PAD4 inhibitors in controlling filament expression and the initiation of gliosis in more clinical settings. 
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4.1 Introduction 
 
Alkali Injury to the eye, as a robust clinical model, has given many insights into the processes of gliosis 
and fibrosis [13, 77, 46]. It also mimics several retinal disorders that have a higher prevalence and 
incidence. For instance, alkali injury leads to an increase in intraocular pressure, such as that seen in 
glaucoma [61, 213]. More severe alkali injuries correspond to higher intraocular pressure [61]. It also leads 
to the upregulation of the type III Intermediate filaments in the cornea (vimentin) and in the retina (GFAP 
and vimentin). In the cornea, this injury induces massive neovascularization and angiogenesis as a 
consequence of fibrosis, which can be targeted with small molecules [13]. In the retina this leads to gliosis, 
an underlying condition in a number of retinal diseases, such as age-related macular degeneration (AMD) 
and glaucoma [46, 77]. This gliosis has been seen in a glaucoma mouse model (DBA/2J mouse line), 
associated with an increase in intraocular pressure [58, 59, 60]. 
We have previously used this alkali injury model to identify citrullination as a major initiator of 
gliosis in the retina. Importantly, we have shown that there is an increase in citrullination in the retina after 
injury and that the major enzyme responsible for this modification, peptidylarginine deiminase (PAD) 4, is 
increased after injury. Importantly, this model is the first to identify that direct injury to the cornea causes 
retinal pathology, highlighting important secondary effects that are not often considered  in 
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a clinical setting [13, 46, 192]. Damage to the cornea increased levels of GFAP, vimentin, PAD4 and 
citrullination, all of which can be targeted in the research setting through the use of small molecules [13, 
77, 46, 169]. The importance of identifying gliosis in ocular disorders that are not primarily targeting the 
retina remains an important but understudied aspect of ocular research. 
Also important is the ability to identify markers of ocular disease and injury severity. While a 
number of different surgical options are available for conditions of the cornea and the lens, clinical 
interventions for the retina are limited. Even though increases in levels of GFAP are an excellent indicator 
of retinal health, the identification of a marker of total ocular health remains an important goal. 
Acknowledging the importance of studies of the intermediate filaments to gliosis and fibrosis in 
ocular diseases, and having identified their upregulation [13, 77, 46], modification by the PAD enzymes, 
and ability to be targeted, we wanted to examine the role of citrullination and the filaments in other models 
of disease, as well as in non-retinal tissues. We set out to test the hypothesis that in glaucoma and alkali 
injury models citrullination of intermediate filaments was increased in ocular tissues, and that  injury 
mimics a number of disease pathologies. 
 
 
4.2 Materials and Methods 
Mice 
Eyes from 8 month old male and female DBA/2J (Jax) and C57BL6 (Jax) were enucleated after sacrifice 
and stored at -80C or immediately frozen in OCT (Tissue-Tek) for immunohistochemistry. WT129SvEV 
mice (Taconic) were used in alkali injuries. 
 
 
Alkali Injury 
 
Corneal alkali injuries were performed in 129S6/SvEVTac (Taconic, Hudson, NY) mice as previously 
described [13, 46] with a minor modification. Mice were given an intraperitoneal (i.p.) injection of  
Ketamine/Xylazine, and corneas were anesthetized with proparacaine eye drops. A 1 µl drop of 1.0N 
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sodium hydroxide was then applied directly to the central cornea for 45 seconds (1.0N). Following injury, 
the eye was immediately flushed extensively with sterile phosphate buffered saline (PBS) solution. The 
corneal epithelium was gently removed using a Tooke knife, and eyes were then treated topically with 
atropine, followed by tobramycin and erythromycin. For time course studies, injured mice were treated 
daily with topical applications of tobramycin and erythromycin for 3 days post-injury and humanely 
sacrificed by CO2 inhalation at different times. 
 
 
Protein extraction 
 
Three mouse eye-cups or three mouse corneas were placed in ice-cold soluble buffer (20 mM Tris buffer, 
200 mM NaCl, 1% NP-40) supplemented with a proteinase inhibitor cocktail (Roche, Indianapolis, IN) and 
tissue was minced into pieces on ice. Samples were left on ice for 45 minutes and then spun at 14,000 
RPM  for  5  minutes  at  4  
o
C.  The  supernatant  was  removed  and  labeled  as  the  “soluble”   fraction 
 
(containing soluble forms of IF proteins), while the pellet was placed into 1:3 diluted β - 
mercaptoethanol:Laemmli buffer to extract cytoskeletal forms of IFs and spun down at 14,000 RPM for 5 
minutes at 4 
o
C. This protein extract was labeled as the “insoluble” cytoskeletal fraction. Both soluble and  
insoluble fractions were then passed repeatedly through a 26-gauge needle 10 times to shear DNA. 
 
 
 
Western Blots 
 
Bicinchoninic Acid Assay (Pierce, Waltham, MA) was used for quantification of protein. Protein samples 
were boiled 95-100 
o
C for 5 to 10 minutes in Laemmli buffer and then loaded on 4-20% Tris-HCl SDS- 
polyacrylamide gels (Bio-Rad). Proteins were transferred onto a 0.2 µm PVDF membrane (Bio-Rad, 
Hercules, CA). Membranes were blocked in 5% milk in 1X Tris Buffered Saline + Tween (TBST) for 1 
hour at room temperature, then incubated with primary antibody for 1 hour at room temperature or 
overnight at 4
o 
C. Membranes were washed 3 times for 15 minutes, then incubated with secondary antibody 
for 45-60 minutes at room temperature. Membranes were washed 4 times for 15 minutes and 
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developed with Enhanced Chemiluminescence (ECL; Bio-Rad) solution. To normalize for protein loading, 
membranes were stripped in 10X Tris-Glycine-SDS buffer for 30 minutes at RT, then probed as above with 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
 
 
Immunohistochemistry 
 
Unfixed eyes were first frozen in OCT (Tissue-Tek, Radnor, PA) at -80 
o
C, before being cut on a cryostat 
at -24 
o
C. Sections were cut at 10 or 15 µm thickness, attached to Superfrost slides and stored at -80 
o
C 
until used. Slides were air dried for 30 minutes and then fixed in ice-cold methanol/acetone (5 min/1 
min). Fixed slides were washed in PBS 3 times for 5 minutes, and then primary antibody was added in 
Dako background reducing solution (Dako, Glostrup, Denmark) at the specified concentration. Slides were 
incubated with primary antibody at 4 
o
C overnight and then washed 5 times for 10 minutes afterwards. 
Slides were then incubated with secondary antibodies at specified concentrations at room temperature in 
the dark for 1 hour, and subsequently washed 5 times for 10 minutes prior to imaging.  
 
 
Antibodies 
 
Primary antibodies used in the experiments included: rabbit polyclonal anti-GFAP (Abcam, Cambridge 
UK, 7779 1:4,000 WB, 1:500 IHC; Abcam 7260 1:20,000 WB, 1:500 IHC), mouse-IgM monoclonal F95 
(anti-peptidyl-citrulline antibody, Millipore MABN328, 1:500 WB 1:200 IHC), rabbit polyclonal  GAPDH 
(Santa Cruz, Dallas TX sc25778 1:500 WB), TGF- β2 (Santa Cruz sc-90 1:250 WB), rabbit polyclonal 
vimentin (Abcam ab45939 1:200 IHC); Secondary antibodies were Santa Cruz goat anti-rabbit IgG HRP 
(sc-2301 1:1000 WB), goat anti-mouse IgG HRP (sc-2302 1:1000 WB), goat anti-mouse IgM HRP 
(Jackson ImmunoResearch, West Grove, PA #115-035-075 1:5,000 WB) goat anti-mouse IgM 488 
(Invitrogen A21042 1:500 IHC), goat anti-rabbit IgG 594 (Invitrogen A11012 1:500). 
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4.3 Results 
 
Citrullination is elevated in the glaucomatous retina at symptom onset 
 
In the DBA/2J model of glaucoma, symptoms that mimic the glaucoma pathology, such as increased 
intraocular pressure, are seen as early as 8 months [58, 59]. We compared DBA/2J retinas at 8 months of 
age to those of age matched C57BL6 mice. There was a marked increase in F95 reactive species 
(citrullinated proteins) at 8 months of age in both soluble and insoluble fractions of proteins in the  DBA2J 
mice (Fig. 4-1A, B respectively). This increase in citrullination precedes any noticeable difference in levels 
of GFAP at the predicted molecular weight between the two mouse strains (Fig. 4-2A), indicating that 
gliotic activity in the glaucomatous retina is at a basal level. Interestingly, we were able to identify  the 
aberrant high molecular weight GFAP in both mouse strains by 8 months of age, although only in the 
soluble fraction (Fig. 4-2A) of proteins, suggesting strain differences in the expression of GFAP. 
 
 
Citrullination occurs along intermediate filaments in the glaucomatous retina 
 
We next wanted to identify the potential targets of citrullination in the retinas of DBA/2J mice. We 
employed immunohistochemical staining of 8 month old C57BL6 and DBA2J eyes for GFAP, vimentin 
and F95 to examine the localization of citrullination along the intermediate filaments, as previously seen 
(Chapter 2). We found that at 8 months, both C57 and DBA2J mice showed immunoreactivity for GFAP 
expression through the layers of the retina, indicating at least a mild ongoing gliosis (Fig 4-3A,D). GFAP 
filaments showed a co-reactivity with citrullinated species in both mouse strains (F95; Fig 4-3 B,E). When 
examining vimentin, both DBA and C57 mice have vimentin filaments throughout the width of the retina, 
extending into the layers of the outer retina (Fig.4-3 G,J). Citrullinated species were also found along 
vimentin filaments, at a greater frequency than along GFAP filaments (Fig. 4-3 I, L). The ganglion cell 
layer in the DBA mice is also disorganized when compared to age matched controls, with GFAP expression 
extending beyond the ganglion cell nuclei (Fig. 4-3C, F, I, L). 
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Figure 4-1. Citrullination in the glaucomatous retina 
 
Western blot analysis of citrullinated proteins (F95) in posterior eye-cups from uninjured C57BL/6 (C57, 
lane 1) and DBA/2J (lane 2) mice at 8 months of age. Protein was extracted from either the soluble (A) or 
insoluble (B) fraction of proteins and run on SDS-PAGE gel. 
88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2. High molecular weight GFAP in the Retina 
 
Western blot analysis of GFAP in posterior eye-cups from uninjured C57BL/6 (C57, lane 1) and DBA/2J 
(lane 2) mice at 8 months of age. Protein was extracted from either the soluble fraction of proteins and run 
on SDS-PAGE gel. (A) Predicted GFAP species in the retina. (B) High Molecular Weight GFAP identified 
in C57BL/6 and DBA/2J mice at 8 months on long exposure. GAPDH loading control from the same 
membrane is found underneath the corresponding lanes. 
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Figure 4-3. Citrullination along Müller Glial filaments in Control and Glaucomatous Retinas 
Immunohistochemical examination of citrullinated proteins (F95), GFAP and vimentin of retinas from 
uninjured mice of either a DBA/2J or C57BL/6 strain at 8 months of age. Glaucomatous retinas (A-C, G- 
I) and control eyes (D-F, J-L) were examined for GFAP (A,D), and F95 (B, E) and merged images (C,F), 
as well as vimentin (G, J) and F95 (H, K) and merged images (I,L). Co-reactive filaments are marked by 
arrows (C, F, I, L). Scale bar = 70 µm 
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Citrullination is increased in the injured cornea 
 
Lastly, as a means of examining total ocular health, we examined the cornea for the PTM citrullination. 
Interestingly, we found a significant increase in immunodetection at ~55kDa and a band at 75 kDa (Fig. 4-
4). This corresponds to a similar increase seen in the retina as early as 1 day after injury (Chapter 2). Unlike 
the retina, there was no band at 50 kDa, but closer to the expected size of vimentin (~55kDa).  
 
 
4.4 Discussion 
 
Here, we have identified an increase in the levels of citrullinated proteins at an early stage of a glaucoma 
mouse model, and the presence of these citrullinated species along filaments of GFAP and vimentin in 
Müller glial cells, before a relevant increase in levels of GFAP protein. The alkali injury we have used also 
surprisingly exhibits glial sprouts, a sign of aging and AMD that may lead to retinal detachments. Finally, 
these citrullinated proteins also accumulate in the injured cornea, although different species appear to be 
citrullinated. Taken in context, this data indicates that citrullination is an important marker of the general 
state of the retina. It also indicates that alkali injury is an important and useful model of  different 
pathologies seen in a number of ocular disorders. 
Glaucoma, from a clinical standpoint, is mainly treated as a disease of the anterior segment of the 
eye [214]. Similar to clinical injuries to the cornea, the retina is often an afterthought. The initial expression 
of citrullinated proteins, before a noticeable increase in GFAP in the retina, in the DBA/2J  mouse model 
indicates that the retina is responding at the same time as the recorded onset of increased intraocular 
pressure, the most well characterized clinical symptom of glaucoma. Combined with the increase in IOP 
that is seen in alkali injuries, and the increase in citrullinated proteins in both the cornea and retina, 
glaucoma appears to have an increase in citrullinated proteins that either precedes or corresponds to the 
major symptomatic presentation of the disease. 
The formation of glial sprouts is common in AMD [40]. Importantly, these sprouts are also thought 
to influence the interaction between the retina and the vitreous [40], and are likely to  be precursors to 
epiretinal membranes that can create retinal detachments [40]. The finding that these glial 
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Figure 4-4. Citrullination is increased in the injured cornea 
 
Western blot analysis of soluble fractions of uninjured corneal tissue or corneas left to recover for 7 days 
after injury. Injured corneas (7d) display immunoreactivity for citrullinated species (F95) at ~75 kDa and 
~55kDa when compared to uninjured control tissue. 
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sprouts are present in alkali injury allows for investigation into their pathology that is less time-sensitive 
than genetic mouse models. 
The identification of alkali injury as a model that mimics a number of different systems has 
provided us excellent insight into the response of the retina in a pathological state. It has also allowed for 
the identification of citrullination as a factor in a number of different diseases and tissues. The in vivo 
control of citrullination remains an important milestone for ocular research. 
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Chapter 5 
 
Discussion, Significance, Working Model, Challenges and Future Directions 
 
5.1 Discussion 
 
The novel inhibitor withaferin A (WFA), which targets soluble forms of the type III intermediate 
filaments (IFs) vimentin and the glial fibrillary acidic protein (GFAP) [14], has proven to be a useful 
pharmacological tool in the study of retinal gliosis [13, 46]. Previous work in the Mohan lab identified this 
molecule as able to alter clinically relevant outcomes in corneal and glaucoma models of fibrosis [67] as 
well as retinal gliosis [13] by specifically altering the regulation of soluble GFAP and vimentin. In my 
thesis work I have examined another regulator of these IFs, the post-translational modification known as 
citrullination. Work shown in the previous chapters identifies a significant increase in levels of citrullinated 
proteins in retinal gliosis, and identified GFAP as a major target of citrullination in the retina. The use of 
PAD inhibitors, supplemented by the use of WFA, was able to downregulate these species in an injury 
explant system, highlighting the importance of being able to target these IFs. Building on previous work, 
which discovered that targeting soluble vimentin in a glaucoma model led to clinically relevant 
improvements [67], I observed citrullination of GFAP and vimentin filaments in the retina in a mouse 
model of glaucoma. Evidence of changes in citrullinated proteins preceded differences in GFAP protein 
levels. This suggests that citrullination is an initiating factor in GFAP expression, a major marker of gliosis. 
This citrullination occurs along GFAP filaments, as does the expression of PAD4 after injury. PAD4 protein 
is also significantly increased after injury. Meanwhile, PAD2 is expressed in astrocytes of the uninjured 
eye, but decreased after injury. Highlighting the importance of PAD4 in the pathological state, the use of 
the PAD4 specific inhibitor streptonigrin was able to decrease accumulation of GFAP when delivered via 
intravitreal injection. These findings of citrullination in the injured retina are mirrored in glaucomatous 
retina as well as injured corneas. It was also discovered that perturbation of vimentin effectively blocked 
the translocation of ERK to the nucleus, identifying a mechanism by which WFA effectively alters the 
soluble function of vimentin [77]. Important to the development of a similar working 
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model in the retina, we found that levels of TGF-β2 protein in retinal tissue were increased early after 
injury and decreased coincident with increased levels of citrullinated proteins (Fig. 5-1). 
Taken together, my findings highlight the expression levels, modifications, and changes to these 
IFs in response to a number of inhibitors after injury and brings to the forefront the necessity of targeting 
and controlling the non-filamentous forms of the type III IF proteins. The sensitivity of phosphorylated 
forms of the IFs to inhibition, and the ability of citrullination to prevent phosphorylation [77] of the IFs, 
provides a foundation on which studies of citrullination in the eye can advance. 
 
 
5.2 Significance 
 
Gliosis is associated with most retinal pathologies. The role of the intermediate filaments in gliosis, 
especially in the retina, is complex. The regulation of these filaments, harnessing both endogenous 
mechanisms such as citrullination and perturbation by small molecules, is an important goal towards 
mitigating any damage from the gliosis process in the retina. To that end, the identification and prevention 
of citrullination in ocular disorders remains an important issue in the development of potential therapeutics 
for eye disorders. 
Fibrosis is also a normal healing process in a number of different tissues throughout the body [215, 
216, 15, 217]. It involves the differentiation of fibroblasts into myofibroblasts as a form of wound healing 
and scarring. This process interferes with the basic function of the cornea, which is to allow light to pass 
through mostly unobstructed. While we have shown that inhibition of the IFs, as well as changes to  their 
post-translational modifications, can dramatically improve outcomes in this condition, there is still 
important insight to be gained by unraveling the role of citrullination in this process. 
One of the most significant results of my thesis work is the finding that an intravitreal injection of 
a PAD inhibitor had a direct impact on gliosis. As intravitreal injections are a common procedure in 
ophthalmic delivery of drugs to the retina, this route of drug delivery can now be exploited for in vivo 
applications in live animals. A second important finding of my thesis work is that the PADs expressed by 
glial cells are responsive to drug effects at both early [Chapter 3] and late [Chapter 2] stages of the injury 
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response. During the courses of diseases in which the pathological condition slowly builds, such as retinitis 
pigmentosa or Age-related macular degeneration (AMD) this is exceptionally important. Symptoms in 
retinitis pigmentosa often begin with the deterioration of dark vision in children, and may not be considered 
a clinical issue until there is significant damage to the retina. Alternatively, the fact that AMD is often 
confused with regular aging can lead to similar pathological conditions without treatment. Citrullination 
has already been identified in humans with AMD, and the ability to target late stage injury may open a 
therapeutic window for this disease. 
My work is the first to show that WFA may have some ability to alter the citrullination process, 
and therefore inclusion of this inhibitor along with PAD-targeting inhibitors could potentially enhance the 
efficacy of PAD inhibition. The complex alteration of high molecular weight species that was observed 
when treated in an explant system [Chapter 2, Fig. 2-8 and 2-9] suggests there is a synergistic effect of the 
two inhibitors, targeting the IFs as an important pathological axis. This synergistic effect of WFA and PAD 
inhibitors on the IFs is a valuable avenue for future research. 
While this work has focused on changes in retinal gliosis and corneal fibrosis, many of the 
mechanistic insights into the control of vimentin and GFAP are likely to be important to other disorders, 
including the epithelial-to-mesenchymal transition in cancer (vimentin) and the increased invasiveness of 
astrocytomas that correlates with the delta isoform of GFAP [218]. The interaction of vimentin and GFAP 
with PAD4, known to be found in a number of different tumors, will likely have to be probed further to 
understand if the interaction between these two players has any role in tumor progression. Additionally, the 
anti-angiogenic activity of WFA, which targets these filaments, highlights the importance of determining  
if citrullination is a major factor in the development of these tumors. 
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5.3 Working Model 
 
Interestingly, in addition to the changes in deimination and the intermediate filaments we have seen 
mentioned above, we have also seen that TGF-β2 is significantly increased early after injury, and 
subsequently decreases with time (Fig. 5-1). It is known that TGF-β2 increases in Müller cells with time 
after retinal detachment, although no information is available for deimination in the same model [219]. It 
has also been theorized that TGF-β2 is an important regulator of retinal progenitor and Müller glial 
proliferation [220] and is released by retinal neurons [220]. This allows for the development of a working 
model of ocular injury that incorporates the responses of the intermediate filaments and of the PADs (Fig. 
5-1). After alkali injury, the change in intraocular pressure likely triggers an influx in calcium into the inner 
retina, initiated by stretched Müller glia and quickly spreading to astrocytes [194, 208, 209, 210]. This 
increase in calcium triggers the activation of the PADs. The PADs then citrullinate a number of proteins, 
including GFAP and vimentin. The citrullination of vimentin likely causes the breakdown of the 
filamentous structure, allowing for the reorganization of vimentin [Chapter 2; 50]. Citrullination of GFAP 
appears to play a role in the breakdown of filaments to reorganize the inner limiting membrane, allowing 
for the glial sprouts seen at 3 days. This also indicates the vimentin breakdown occurs with citrul lination, 
and may act as a method to increase incorporation of GFAP along vimentin filaments. Citrullination of 
GFAP may also allow for the interaction with PAD4, which is seen along GFAP filaments. This interaction 
likely plays a role in the movement of PAD4 toward Müller cell nuclei, where it can subsequently alter 
gene expression to trigger Müller glial reactivity in the retina. This may cause the downregulation of TGF-
β2 activity, in turn minimizing Müller glial proliferation and differentiation early after injury. 
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Figure 5-1. TGF-β2 is increased early after injury 
 
(A) Western blot analysis of TGF-β2 in the posterior eye cup of uninjured (unj) mice or mice subject to 
alkali injury and left to recover for 1 day (1d), 3 days (3d), or 7 days (7d) after injury. (B) Densitometric 
quantitation of TGF-β2 immunoreactive bands using ImageJ (*=p<.05, students t-test). 
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Figure 5-2. Working Model of Muller glial reactivity after injury 
 
Muller glial cells in an uninjured state contain full length vimentin filaments, with minimal GFAP 
expression, PAD expression or Citrullination. After injury, these are all increased immediately. TGF-β2 
may act upon Muller glial cells, either from Muller glia or from retinal neurons, to immediately enhance 
proliferation. PAD4 is increased in a chronic injury, shutting down TGF-β2 related proliferation. Modified 
from [22]. 
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5.4 Challenges 
 
One of the major challenges when examining citrullination in the retina is the lack of functional 
knowledge outside of the context of rheumatoid arthritis (RA). While vimentin in RA becomes an auto- 
antigen [221], the same has yet to be observed in the retina with regards to GFAP. It is necessary to note, 
however, that this may be a consequence of few clinical studies into the field, as the field is still in infancy 
regarding the role of citrullination in retinal disorders. Citrullination of GFAP, vimentin, and desmin has 
been studied in vitro, however [33]. Initial findings strongly suggest that citrullination of the type III IFs 
inhibits phosphorylation, necessary for the reorganization of insoluble forms of the IFs as well as the control 
of the soluble forms. This study also found that filament formation of GFAP and vimentin was prevented 
after IF proteins were incubated with PADs. 
The challenges present in the study of intermediate filaments stem from their dynamic nature and 
the traditional methods for examining their expression. As is becoming clearer, static images, while useful, 
are more difficult to interpret for a cytoskeletal structure that is capable of exchanging subunits along its 
entire length. This exchange allows for interactions with different proteins to be transported or modified 
along the length of the filament. While live imaging may capture this, it is difficult  to identify small but 
important events through static imaging. The use of live cell imaging will likely become increasingly 
important in the study of both the soluble and insoluble fraction of filaments. Additionally, the 
overwhelming abundance of cytoskeletal intermediate filaments makes interpretation of 
immunohistochemistry that identifies the less abundant soluble form difficult. For this reason, assembly 
dynamics will likely need to be studied in depth in cell cultures, with insights gained from these  studies 
tested in vivo later. 
In conjunction with this, another major challenge is the fact that the biochemical identity of the 
high molecular weight GFAP species that can be observed by western blotting is still unknown. While 
several articles have observed a species above the predicted value, few made any mention into its relevance. 
Others show the expected bands only, which prevented any insight into our interpretations of this aberrant 
expression of GFAP. Ultimately, we were able to attribute some portion of this aberrant 
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species to the hypercitrullination profile we observed. These species likely represent aggregates  of 
protein, such as those found in Alexander Disease, although this still needs to proven experimentally.  
Another major challenge is the overwhelming number of arginines found in both GFAP [93] and 
vimentin [96]. It appears that citrullination occurs on many of these sites, as indicated by our results from 
a 2-dimensional separation of protein lysates from injured retina when probed with a citrullinated GFAP 
antibody. As GFAP becomes citrullinated, the epitopes appear to become less reactive to GFAP antibodies, 
as has been noted [19]. This biochemical phenomenon, in conjunction with the abundance of a number of 
both modified and non-modified forms in the injured lysate, made direct identification of the citrullinated 
sites of GFAP difficult, although two citrullinated sites (R267 and R413 in mice) were identified in injured 
retinas. 
 
 
5.5 Future Directions 
Pressure and Glial Reactivity 
One of the most important aspects of study that remains from this work is the understanding of the 
interplay between intraocular pressure (IOP) and the increase of levels of citrullinated proteins. In the intact 
in vivo alkali injury experiments presented here, there is a set of distinct citrullinated bands that are present 
in the injured eye. In the eye-cup explant system used, however, there is a robust hypercitrullination, leading 
to a number of unexpected species of filaments. When the eye was enucleated and incubated as an intact 
globe for 5 hours, as in the streptonigrin experiments described in chapter 4, the pattern of citrullination 
returned to that seen in vivo. A quick assessment of this pattern can be accomplished through a stepwise 
increase in the size and severity of cut in the eye. With a small incision, little structure is lost within the 
globe. With incisions increasing to one quarter, one half, or total removal of the eye-cup, the citrullination 
profile after 5 hours can be assessed as a means of identifying globe integrity, as a proxy of intraocular 
pressure regulation, as necessary to prevent a hypercitrullination profile. 
101  
With insights into IOP that we gain from the glaucoma system, the regulation of pressure appears 
to be important as either a sensor for the rest of the retina or a trigger to initiate gliosis. Indeed, astrocytes 
exposed to an experimental stretch showed an increase in deimination [183]. This can most effectively be 
addressed in vivo in two different models. First, the genetic DBA/2J mouse model can be treated long term, 
starting at 5 months, with a PAD inhibitor to determine if glaucomatous outcomes can be changed. Second, 
an experimental model of glaucoma in rabbits treated with intravitreal injections of pan-PAD inhibitors 
such as Cl-amidine or PAD4 specific inhibitors such as streptonigrin will allow us to determine if the 
increase in IOP after experimental glaucoma directly alters outcomes for glial and neuronal cells, and if the 
process can be mitigated by the PAD inhibitors. 
We would also hypothesize that WFA can directly alter the citrullination profile of glial cells in 
response to pressure and stretch. Examination of primary glial cultures in a standardized pressure system 
[223], which can apply pressure in a gradient from a focal point, either pre-treated or treatment following 
pressure with varying doses of WFA could provide insight into the ability of WFA to target citrullinated 
IFs. It is likely that the expression of citrullinated proteins, as they interact with phosphorylated proteins, 
will decrease, as WFA can target GFAP. This system could also be used with a biotin tagged WFA to  
determine the capability of WFA to target citrullinated forms of GFAP, as has previously been used to 
determine both vimentin [14] and GFAP [13] binding. 
 
 
 
Identification of Citrullination sites on GFAP and Vimentin 
 
Identification of specific citrullination sites on GFAP and vimentin will allow for better studies 
into specific changes that occur on the filaments, and how each affects the biophysical properties of the 
protein. Gleaning insight from the changes that are known to occur to vimentin with phosphorylation [77], 
and the interaction of citrullination with phosphorylation on the filaments, it will be very important to 
identify the sites citrullinated as well as the domain each belongs to. As a practical approach, it will be 
necessary to mutate the sites in each domain in a GFAP-GFP construct. Ideally, all arginine sites within 
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the head domain, the rod domain, or the tail domain will be mutated and transfected into GFAP-negative 
primary astrocytes. The induction of citrullination after stretch [223] or in response to nanoparticles [224] 
can then be examined under electron microscope to identify effects of domain-specific citrullination on 
polymerization of GFAP and, in similar experiments, vimentin. 
To that end, studies harnessing WFA to examine the impact it has on the citrullination of its targets 
is likely to be an important, although extremely complex, future avenue for studies. The finding that 
hyperphosphorylation of vimentin makes myofibroblasts sensitive to WFA perturbation in the soluble form 
suggests that citrullination, thought to break down filaments, would be involved in the switch in a 
phosphorylation-dependent role. If citrullination is involved in the breakdown of filaments, and the soluble 
form of vimentin more sensitive to perturbation, we would hypothesize that mutations to arginine that  
prevent citrullination would alter the course of fibrotic initiation. 
 
 
Functional Effects of Citrullination on the IFs GFAP and vimentin 
 
Functional assessment of the effect of citrullination on GFAP and vimentin has not been studied 
thoroughly. Studies into the assembly and disassembly mechanics will require a movement from the in vivo 
system into a cell culture system, in which GFAP-GFP or Vim-GFP astrocytes can be visualized in live 
cells in real time to determine how changes in citrullination, induced either by the pressure system described 
[223] or in response to nanoparticles [224] in a culture dish alters the assembly dynamics. This will also 
involve the use of calcium chelators, such as EGTA, to act as a control and limit PAD activity.  
The interaction of GFAP with the ubiquitin proteasome pathway is an interesting avenue that needs 
more attention, as this interaction is dramatically altered in Alexander disease [79]. It is of great interest 
that not only does mutated GFAP alter this interaction, but overexpression of wild-type GFAP significantly 
alters proteasomal activity [225]. Using the explant system we have described to cause hypercitrullination 
and aberrant GFAP expression, we can use the proteasome inhibitor epoxomicin to examine increases of 
these aberrant species, as we would hypothesize. We can also examine the different components of the 
proteasomal process in the presence and absence of the IF modifier WFA. It will  also 
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be important to identify changes in this interaction after use with the PAD inhibitors to examine any 
effects of citrullination. 
Interestingly, the zebrafish retina is capable of regenerating retinal neurons, and only has one PAD 
enzyme, closely resembling PAD2 [104]. The chicken retina is partially capable of neuroregeneration, and 
has 3 PAD enzymes. The mouse, rat, and human retina are incapable of endogenous neuroregenration, and 
have 5 PAD enzymes. It will be interesting to determine in vivo if the effects of PAD inhibition, both from 
a genetic and a pharmacological deficiency, an approach we have employed in the past [153, 67, 15, 13, 
14], has an effect on the proliferation and dedifferentiation of Müller glial cells. In this approach, the PAD2 
knockout [112] and PAD4 knockout [125] mice should be crossed to form genetic knockouts of the two 
PADs present in the retina, and the alkali injury model used in this system to initiate gliosis. Examination 
of glial markers in this system, including GFAP, but also proliferation markers (Ki67) [226] and 
dedifferentiation markers (Ascl1a) [227], will give clear insight into the role of citrullination and the 
filaments in Müller glial response. The intravitreal injection of PAD inhibitors, both with and without WFA 
as a co-injected molecule, in the alkali injury model, as well as in laser injuries, will open up a therapeutic 
avenue into treatments for human retinal disorders. 
Citrullination in other CNS disorders and disease models 
 
Glaucoma is also known to involve changes in citrullination. Specifically in humans, citrullinated 
proteins and PAD2 levels are increased in the optic nerve, which can be severely damaged in glaucoma 
[228]. Continued experiments with the DBA/2J mice that are a good genetic model of glaucoma will give 
excellent insight into the role that citrullination plays in the glaucoma process. While characterization of 
the glaucoma timeline as it pertains to citrullination needs to be established, the tools to examine disease 
onset and severity also exist in the form of the PAD and IF inhibitors. Studies measuring intraocular 
pressure, glial reactivity and ganglion cell death [229] after weekly treatments with WFA or Cl-amidine 
will allow for the role of citrullination in glaucoma to be more firmly identified. Ultimately, glaucoma 
represents the most relevant clinical paradigm in which to examine the therapeutic effect of PAD inhibition 
in the eye. 
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Corneal fibrosis involves the reactivity of stromal keratinocytes and their ultimate differentiation 
into myofibroblasts [77]. Our discovery that citrullination is occurring in a fibrotic cornea, in a pattern 
reminiscent of vimentin expression, is an indicator that not only is phosphorylation of the filaments an 
important switch to initiate fibrosis, but that citrullination is a response in this same pathway. Studies 
determining the targets, effects, and inhibition of citrullination in the cornea, similar to those described in 
the retina, will help establish the role of citrullination in fibrosis in a global sense. 
Age-Related Macular Degeneration (AMD) involves the degradation of the macula in the aging 
population. There is an increase of PAD2 levels and deimination in the AMD population [38]. Insight  into 
the relevance of citrullination in AMD in humans is limited, however, to these levels of expression. It will 
be interesting to examine post-mortem tissue of AMD patients for citrullinated GFAP and vimentin. 
Alternatively, it will become important to identify changes in deimination in human tissue with aging, as 
both AMD and age-matched control eyes expressed deimination markers [38]. More important is the 
relation of citrullination to gliosis, a factor within AMD. Many of the insights into gliosis will be beneficial 
to the treatment of AMD as a long-term clinical goal. Supplementary clinical treatment with PAD inhibitors 
as a therapeutic to attempt to downregulate glial reactivity in AMD will be an intriguing topic. 
5.6 Conclusions 
 
The presence of citrullination in our alkali injury model was a novel finding that we were able to 
relate to a number of other diseases and experimental models. Importantly, it appears to play a major role 
in the initiation of gliosis, a factor in a number of different retinal, brain and spinal cord pathologies. The 
work reported in this thesis represents a substantial contribution to the fields of citrullination, retinal gliosis, 
and the type III intermediate filaments, and will hopefully help to provide insights for researchers in a 
number of different systems. 
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